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ABSTRACT
MOUSE OOCYTE MATURATION AND EMBRYO DEVELOPMENT AFTER 
EXPOSURE TO VEMURAFENIB (PLX4032), AN ANTI-MELANOMA B-RAFV600E
INHIBITOR
Bo Liu
Old Dominion University, 2014 
Director: Dr. R. James Swanson
Vemurafenib is a selective B-RafV600E inhibitor in melanoma targeted therapy 
which also inhibits the wild type B- and C-Raf. In oocyte maturation, the C-Raf/MAPK 
pathway acts as an important self-enhancing and promoting system, whereas in embryo 
development, the C-Raf/MAPK pathway participates in pre- and post- implantation 
embryo proliferation and differentiation.
The hypothesis: Vemurafenib has detrimental effects on oocyte maturation and/or 
embryo development. Mouse oocytes and one cell (1C) mouse embryos were tested by 
ex vivo culturing with Vemurafenib in serial dilution. Oocytes were evaluated by cell 
cycle morphology, spindle formation and chromosomal alignment by 
immunofluorescence (IF) staining as well as DNA integrity by Terminal Transferase 
dUTP Nick End Labeling. Embryo development was evaluated by morphological 
changes and the C -Raf bioactivity via a p-M ek 1/2 IF assay. In vivo exposure and 
subsequent morphological evaluation o f  ex vivo two-cell (2C) embryo development was 
conducted by pre-injections o f Vemurafenib (10 mg/kg).
Ten pM or above produced oocyte toxicity, spindle formation disturbance, 
chromosome misalignment and DNA damage, whereas the therapeutic Vemurafenib 
concentration 1 pM did not display significant oocyte morphological toxicity to ex vivo 
oocyte maturation, spindle formation, chromosome alignment and DNA integrity.
Ten pM and 100 pM showed phosphorylation inhibition o f embryo Mek 1/2. 
decreased C-Raf activity and obvious toxicity to 1C to 2C transition. However, the 1 pM 
Vemurafenib was not shown to have significant ex vivo preimplantation 1C embryo 
development toxicity on the 1C to 2C transition and no effect on C-Raf activity.
Ten mg/kg Vemurafenib pre-injections demonstrated only a mild delayed toxic 
influence throughout the embryo development. However, the majority o f embryos
progressed to normal blastocysts and did not show significant in vivo degenerative 
preimplantation embryotoxieity.
Thus Vemurafenib, at its therapeutic concentration, was free o f  ex vivo oocyte and 
embryo morphological toxicity, but in vivo toxicity needs further clarification on 
mechanisms and survivability o f  collapsed unhatched embryos.
VThis thesis is dedicated to my Lord Jesus Christ, my mother Wang, Lin, my wife Huang. 
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CHAPTER 1
INTRODUCTION
1.1 The Epidemiology of Malignant Melanoma (MM) with Pregnancy
Vemurafenib is an anti-cancer drug used in targeted chemotherapy for MM. 
Vemurafenib is not recommended for use in women that are pregnant or suspected to be 
pregnant because Hoffman La Roche, the patent holder, has not tested and most likely 
does not intend to test this drug for safely in embryo or fetal stages o f  mouse or human 
development. (FDA Reference ID: 3001518) Therefore a woman that is diagnosed with 
MM where Vemurafenib is the treatment-of-choice for the disease might have to choose 
between delivering a healthy neonate or death for both her and the child if  she is pregnant 
at the time o f diagnosis and treatment initiation. A clear understanding o f the toxicity o f 
Vemurafenib to the female gamete, pronuclear stage cell, and zygote-to-blastocyst stages 
is the initial starting point for understanding the potential dangers o f Vemurafenib. If  the 
toxicity is low enough to suggest use o f Vemurafenib during pregnancy then further 
research could be performed on long-term effects to male and female gametes and on 
teratogenicity to the fetus/neonate.
In the United States (US), malignancies account for about 19.9% o f the mortality in 
women between 15 and 34 years o f age (Pavlidis, 2002). The MM is one o f the leading 
causes o f  all malignancies and non-accidental deaths o f women in the US (Langagergaard 
2011). Approximately 61,300 cases o f  melanoma were diagnosed in situ  in 2013 (Siegel 
et al., 2013). “The incidence o f  MM in pregnancy has been estimated to range from 0.14 
to 2.8 per 1,000 live births and melanoma accounts for about 8% o f all malignant tumors 
arising during pregnancy” (Em stoff MS et ah, 2003). An increasing numbers o f 
pregnancies in older women will result in more melanomas being seen. Women who 
often postpone their childbearing plans for various reasons make up one third o f women 
diagnosed with MM in the US childbearing age (Lens et ah, 2008). This data gives clear
2direction for discovering the toxicity o f Vemurafenib when used during pregnancy.
1.2 The Etiological Role of B-Raf in MM
While there is no current evidence for B-Raf in the mammalian eggs, the existence 
o f B -Raf in the Xenopus levis has been documented (Sergiy I. Borysov et al.. 2008). The 
fact that Vemurafenib is designed to target the mutated B -Raf does not exclude the role 
o f  wild-type B- and/or C-Raf in the process o f  mouse oocyte and embryo development. 
Therefore, understanding B -R af s role is crucial in understanding C -R af s role. The 
binding inhibition for mutated B-RafV600E is 31 nM; for wild-type B-Raf is 100 nM; and 
for C -Raf is 48 nM (Bollag G, et al., 2010). Based on the binding data, we can say that 
toxicity to normal wild-type oocytes and embryos is relevant in understanding the 
potential toxicity o f  Vemurafenib on oocyte and embryo development. The Raf 
serine/threonine protein kinases, including A- (68 kd), B- (95 kd) and C -R af (74 kd). 
serve as the major downstream effectors o f the Ras in the Mitogen-Activated Protein 
Kinase (MAPK) pathway. The MAPK signaling is activated by growth factors and/or 
cytokines through the receptor tyrosine kinases (RTK) which in turn activates Ras 
(Davies et al., 2002; White, 2011; Sosman et al., 2009). Mek is the only known substrate 
o f  B-Raf and C -Raf (Dhomen et al., 2007). The B-Raf mutation accounts for 50% o f all 
melanoma cases, the majority o f  which are produced from unprotected intermittent UV 
exposure (Davies et al., 2002). Targeting melanoma B-RafV600G mutation with 
combination therapy has become the focus o f  ongoing clinical trials.
1.3 The Pharmacology of Vemurafenib
Vemurafenib. a crystalline form o f PLX4032, is a highly selective mutated B- 
RafV600B kinase inhibitor (Sharma A, 2012). Vemurafenib is approved by the FDA 
because o f  its overall increase in survival rate and free progression period than its 
classical chemotherapeutic agent, dacarbazine in MM (Chapman et al., 2011). However, 
in vitro . siRNA-induced mutated B-RafV600E silencing leads to a decrease o f  downstream 
Erk activation and. to some degree, o f apoptosis whereas the WT B-Raf silencing has a
cFigure 1. Vemurafenib’s Pharmacological Mechanisms
(A) In vivo p (phosphorylated)-B-RafV600E mutated monomer in Melanoma. Vemurafenib 
completely blocks B -Raf activity o f Mek phosphorylation. (Sharma A et al., 2012).
(B) In vitro Wild Type (WT) p-A-, p-B-, p-C-Raf monomer in other cells. Vemurafenib 
shows in vitro inhibitory effects on WT phosphorylated A-, B- and C-Raf and is 
potentially harmful to cell types such as like oocytes and embryos. (Poulikakos et al.,
2011, Bollag G, et al.,2010)
(C) In vivo WT p-B-RAF homogenous & heterogeneous dimer in Melanoma. A low 
dose o f Vemurafenib in vivo transactivates Mek by heterodimerizing with C-Raf, while a 
high dose o f Vemurafenib blocks such an effect (Poulikakos et al., 2011; Heidom, 2010; 
Hatzivassiliou, 2010).
trivial influence on melanoma growth (Hingorani et al., 2003). Moreover, several recent 
in vivo studies point to results similar to the in vitro B-Raf silencing test. In patients with 
both mutated and WT B-Raf melanoma cell, Vemurafenib not only inhibits B-Raf in the 
mutated B -Raf cell, but also causes MAPK pathway activation via transactivated C-Raf 
in W T B-Raf cells (Poulikakos et al., 2011; Heidorn, 2010; Hatzivassiliou, 2010).
4Vemurafenib also inhibits M ekl/2 and E rk l/2  phosphorylation (Yang et al.. 2010).
Figure 3 compares the MAPK pathway transactivated via C -Raf in vivo (Figure 3C) with 
in vitro inhibition o f WT B-Raf and C-Raf (Figure 3 A). This activation results from 
transactivation o f non-inhibited C-Raf dimerized with inhibited WT B-Raf. The mutated 
B-RafV600E cell monomer (Figure 3B) is inhibited (Poulikakos et al.. 2011; Hatzivassiliou, 
2010). In recent Vemurafenib phase I clinical trials, 90% o f patients carrying the B- 
RafV600t mutation showed confirmed tumor shrinkage, with remarkable Erk signaling 
inhibition (Chapman, 2009; Flaherty, 2009).
1.4 Normal Oogenesis, Folliculogenesis, Morphology and Molecular Basis
1.4.1 Early Oogenesis: Primordial Oocyte to Primary Oocyte (Primordial Follicle)
A spermatozoon and an oocyte each provide half the genetic materials for embryo 
development and all the cytoplasmic materials for early (1C to 2C) embryo development.
Female oogenesis begins in the fetal ovary while in the uterine development and 
continues throughout reproductive stages. It is generally accepted that all oocytes in the 
ovary develop before the birth o f  the female fetus. In the fifth week o f pregnancy, the 
primordial germ cells in early female fetal development multiply and slowly migrate 
from the yolk sac epithelium to the genital ridge, form the primitive medullary and sex 
cords, and later form the shape o f the ovary. After this migration and proliferation, an 
estimated one to two thousand primordial germ cells, now called oogonia, are located in 
each ovary. This number increases by mitosis to approximately six to seven million 
oogonia by the fifth month o f gestation (20th week) when proliferation ceases.
While growth factors, PGs, transforming growth factor beta (TGF- p) (Pangas SA et 
al., 2012), bone morphogenetic proteins (BMPs) (M argulis S et al., 2009) and 
antimullerian hormone (AMH) (Durlinger AL et al., 2002) are considered to be important 
in fetal ovary development. Information concerning the hormonal or factorial controls 
and regulations remains unclear.
Some oogonia located in the inner layer or ovarian cortex increase the size o f  the 
cell and perform drastic nuclear changes for further meiotic development. These cells are 
now called primary oocytes. These changes are endocrine independent. The DNA o f the
5primary oocyte replicates to form the sister chromatids, which are paired homologously 
with the same parental-oriented chromatids as the tetrads. The cells then enter meiosis. 
The cells arrest in meiotic prophase I at diplotene and is surrounded by a single flattened 
cuboidal layer o f  somatic epithelial cells (pre-granulosa cells). The primary oocyte- 
encapsulated somatic epithelium complex is now called the primary follicle. Oogenesis 
is closely connected with the folliculogenesis (Makabe S et al., 2006).
Once arrested, further development o f  the primordial follicle ceases until the 
initiation o f sexual maturity in puberty. The primordial follicles remain in the resting 
state. Not every oogonium will successfully develop to form a primordial follicle. 
Depending on individual variation, only 50% to 90% o f the fetal ovarian oogonia will 
finally enter the meiotic stage. The remainder o f  the oogonia, which failed to form 
primary oocytes and/or primordial follicles, undergo the physiological degenerative 
process called atresia. Only approximately two million primordial follicles will survive 
until the birth o f the female fetus. However, the loss o f gametes is a continual apoptotic 
process o f  the primordial follicles. From the 20th week o f gestation through pre-puberty, 
atresia o f primordial follicles beginning with the death o f  the primary oocyte decreases 
the total number o f  primordial follicles to three to four hundred thousand by the onset o f 
puberty (Tingen CM et al., 2009). By the onset o f  menopause at 45-55 years, all oocytes 
have been depleted and 99.9% o f primordial follicles have never matured. The 
degradation o f oocyte selection does not appear to be based on quality (Hartshome GM et 
al., 2009).
1.4.2 Early Folliculogenesis and Endocrine Hormone Regulation
Onset o f puberty is marked by the pulsing release o f the gonadotropin releasing 
hormone (GnRH). Leptin is the putative initiator o f  GnRH release. Leptin receptors are 
located at the preoptic nucleus o f the hypothalamus, where GnRH synthesis occurs.
Leptin depletion leads to failure o f GnRH release and the onset o f puberty. Also, 
kisspeptin, the product o f  the gene K issl, a G-protein coupled receptor ligand for GPR54, 
is originally identified as a human metastasis suppressor gene that has the ability to
6suppress melanoma and breast cancer. Kisspeptin-GPR54 signaling is understood to play 
an important role in initiating GnRH secretion at puberty.
GnRH, released from the hypothalamus and transported to the anterior pituitary 
gland via the infundibulum (hypothalamo- hypophyseal portal blood vessel system), 
stimulates the synthesis o f the Follicle-Stimulating Hormone (FSH) and Luteinizing 
Hormone (LH). Both FSH and LH bind to their G-protein coupled receptors and activate 
the adenyl cyclase. Adenyl cyclase converts the ATP to cAMP, which in turn stimulates 
the protein kinase A (PKA) for further biological functions. FSH in the female stimulates 
estrogen secretion, mainly estradiol, growth o f the ovarian follicles, and oocyte 
maturation; whereas LH facilitates luteinization o f the follicle, ovulation stimulation and 
the progesterone secretion by the corpus luteum.
The activation o f  primordial follicle growth by FSH and LH is considered an 
irreversible process for the follicles toward either atresia or the mature Graafian follicle. 
In the primary oocyte, under the influence o f systemic gonadotropins FSH and LH, the 
cell increases its total cytoplasm and secretes the zona pellucida, a transparent protective 
shell composed o f four glycoproteins.
At the same time, the increase o f FSH and LH concentration during the early stage 
o f the menstrual cycle stimulates the numbers and layers from the single surrounding 
flattened layer to multiple cuboidal layers o f  granulosa cells, which in turn secrete 
transuding plasma inside the follicle and significantly increase the size o f  the follicle.
This fluid-filled space, the antrum, is composed o f multiple various-sized chambers. , 
Under the influence o f LH, the thecal cell layer differentiates into the theca interna and 
theca externa. After this differentiation, the follicle is called a secondary follicle. Both 
granulosa cells and thecal cells are steroidogenic cells and are separated by a glassy layer 
o f basement membrane.
Androstenedione is synthesized from cholesterol in the theca interna under the 
influence o f  LH and is delivered to the inner granulosa cells where it is synthesized into 
estradiol under the influence o f  both FSH and LH. Estradiol, the most biologically active 
estrogen, is responsible for the significant changes o f  secondary sex characteristics as 
well as oviduct and uterine preparation for the embryo implantation. Such preparations 
include enlarged and ciliated epithelia in the oviduct, increased size o f the uterus and
7stimulated epithelial, glandular and stromal cell proliferations o f  the endometrium. These 
cells become the secretory tissue in response to progesterone in the luteal phase in 
preparation for embryo implantation (Hedge G et al., 1987).
1.4.3 Graafian Follicle Formation
As the level FSH and LH increases, the number o f granulosa cells increases. These 
granulosa cells are responsible for the fluid accumulated in the antrum. Multiple 
follicular pockets o f  fluid coalesce into a single tertiary follicle and finally form the 
Graafian follicle. As the antrum enlarges, the granulosa cells immediately adjacent to the 
primary oocyte are called corona radiata. The close contact o f  these cells to the primary 
oocyte through specialized gap junctions is critical to oocyte maturation resumption in 
information signaling and nutrition transportation and exchange. A group granulosa cells 
draws the primary oocyte off-centered to one side o f  the follicle, forming a cumulus 
oophorus. The cumulus oophorus in turn attaches to the mural granulosa cells, which are 
pressed by the antral fluid against the follicular wall like a stalk. The Graafian follicle, 
also known as the tertiary or preovulatory follicle, reaches the size o f 12 to 19 mm. This 
dramatic change in size results in one Graafian follicle bulging and thinning one surface 
lining o f the tunica albuginea, which is the dense connective tissue lining o f  the ovary.
1.4.4 LH surge, Follicular Rupture and Ovulation
Approaching day 14 o f the normal 28 days o f the menstrual cycle, the anterior 
pituitary produces a surge o f  LH in respond to the positive feedback o f the estradiol 
secreted by granulosa cells. LH directly induces oocyte meiosis I resumption (section 
1.5.6), and also causes the mural granulosa and cumulus cells to produce a minimal 
amount o f  follicular steroid hormone (progesterone), which indirectly induces oocyte 
maturation and initiates the ovulation process. Progesterone then causes follicular 
hyperemia and PGs secretion. As follicular fluid production and swelling increase 
(Russell DL et al., 2007), granulosa cells begin secrete proteolytic enzymes (like 
collagenase) to weaken the follicular wall o f the Graafian follicle. The follicle swelling
8and wall weakening lead to a blister-like thinned area called stigma. The stigma 
eventually ruptures and expels the secondary oocyte under the influence o f LH (Peters H 
et al., 1980).
1.4.5 Oocyte Nuclear Maturation Morphology
By definition, oocyte maturation begins with meiotic prophase I. The arrested 
primary oocyte resumes its first meiotic division to progress into and arrest at meiotic 
nuclear metaphase II. which produces a secondary oocyte and accompanying cytoplasmic 
changes for proper conditions for fertilization and early embryo development. Therefore, 
both nuclear and cytoplasmic maturation are essential criteria for oocyte quality 
evaluation.
The most important feature o f  the arrested prophase I primary oocyte is its 
prominent microscopically intact nucleus, known as a germinal vesicle (GV). Inside the 
GV, the nucleolus can be clearly visualized by light microscope (Brunet S et al., 2007).
In the Graafian follicle, formed by the LH surge, the most prominent microscopic 
structure is the metaphase II plate.
A very thin narrow space called the perivitelline space is located between the 
oocyte plasma membrane (oolemma) and the zona pellucida. The width o f  the 
perivitelline space is one o f  the critical criteria in assessing the quality o f  the secondary 
oocyte and embryo before implantation after the collection operation.
Meiosis resumption is characterized by the disappearance o f  the nuclear membrane 
and condensation o f the chromatins into chromosome pairs aligned on the center o f the 
barrel-shaped meiotic spinal apparatus at meiosis metaphase I. This dissolution o f  the 
nuclear membrane is termed germinal vesicle breakdown (GVBD). After separation o f 
the paired chromosome at meiosis telophase I, the oocyte squeezes out its first polar body 
into the narrow perivitelline space, which contains half o f the genetic materials with very 
little amount o f cytoplasmic content. Then the oocyte progresses into meiosis II without 
being arrested in prophase, without DNA replication. Again, the chromatins o f the 
oocyte at meiosis metaphase II are condensed and paired, aligning along the center o f  the 
barrel shaped meiotic spinal apparatus. The oocyte finally arrests at metaphase II to
9await the signal to resume meiosis II after sperm penetration (oocyte activation).
1.4.6 Oocyte Cytoplasmic Maturation from Meiosis I Resumption to Meiosis 11 
Arrest and Its Molecular Biology
Oocyte cytoplasmic maturation involves integration o f the interaction o f  cumulus 
granulosa cells and the oocyte. Both cell types operate under the influence o f  hormone 
changes, and the oocyte’s intracellular signaling network o f  cellular events (Meiosis I 
resumption, GVBD meiotic metaphase II arrest, and eventual ovulation). The steps o f 
maturation involve:
•  Surrounding cumulus granulosa cell regulation o f oocyte cytoplasmic maturation. 
Meiosis prophase I arrest o f the primary oocyte and the maintenance o f the arrest 
state require bi-directional signaling communication between the cumulus granulosa 
cells and the oocyte. From the very beginning o f folliculogenesis, the primary oocyte 
is responsible for the surrounding granulosa cells for their proliferation, 
functionalization, and differentiation. Developing granulosa cells build up the direct 
communicating gap junction channels by stringing themselves together and extending 
the cell membrane endings through the zona pellucida to the primary oocyte. These 
cell-to-cell communications convey the nutrient and signaling messages between 
granulosa cells and oocyte for maturational competence and the maintenance o f  the 
arresting state (Gershon E et al., 2008).
•  Cx37 (also known as GJA4) is the major connexin (Cx) o f the gap junction 
components between the cumulus granulosa cell and oocyte, whereas the Cx43 (also 
known as GJA1) is the gap junction component among the granulosa cells. The 
disruption and breakdown o f the gap junction communication by the LH or human 
chorionic gonadotropin (hCG) are the characteristic signs o f the primary oocyte 
meiosis I resumption (Kalma Y et al., 2004).
•  LH binding to its G-protein coupled receptor in cumulus granulosa cells activates the 
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Figure 2. Signalings in Cumulus Cells Regulates Oocyte Maturation in LH Surge
The high c-AMP content delivered from cumulus cell to primary oocyte via Cx43 
composed gap junction is the primary force o f maintaining GV-intact oocyte from GVBD 
(Downs & Eppig 1984, Downs et al. 1986). The c-AMP in oocyte phosphorylates 
Cdc25B, an MPF inhibitor, via PKA keeps the GV-intact state (Gautier J et al., 1991).
LH acts through G-protein-coupled receptor which in turn activates cAMP/PKA 
pathways to enhance the biosynthesis o f EGF factor in cumulus cell (Conti M et al., 
2002). EGF factor in turn activates the Ras/Raf/Erk 1/2 MAPK pathway mediates the 
oocyte meiosis resumption by phosphorylating downstrean effectors, nuclear 
transcriptions and gap junctions closure by Cx43 connexin phosphorylation(Kalma Y et 
al., 2004, Qing-Yuan Sun et al., 2009). IGF-1 activates PDE3 to degrade c-AMP in 
cumulus cell via 1-R/PI3K pathway. IGF-l-Ras-Raf-M APK pathway also acts as the self­
enhancing and self-accelerating system in progesterone induced Mos-MAPK-GVBD 
(Bodart et al., 2005). LH-R (LH receptor), PDE3 (Phosphodiesterase 3), I-R (Insulin 
receptor), IGF-1 (Insulin-like Growth Factor-1), P (Progesterone). P-R (Progesterone 
receptor), GVBD (Germinal vesicle breakdown), MPF (Maturation Promoting Factor)
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inhibits the expression o f  the Cx43 by phosphorylation, and disrupts the cell-cell gap 
junction communication (Conti M et al., 2002). Deletions o f  the MAPK effectors, 
Erkl and Erk2, significantly block the gap junction breakdown. The LH-induced 
paracrine o f  progesterone from the surrounding cumulus cells towards the primary 
oocyte plays a pivotal role in adenyl cyclase inhibition, which decreases the total 
concentration o f cAMP, and promotes the oocyte maturation promoting factor (MPF) 
complex formation.
•  LH-induced epidermal growth factor (EGF) via cAMP/PKA, Ras and MAPK 
pathways together act as the intrafollicular gonadotropin-related signals from the 
cumulus granulosa cells to the primary oocyte. However, the detailed mechanisms 
remain elusive (Qing-Yuan Sun et al., 2009). Furthermore, insulin and insulin-like 
growth factor 1 (IGF-1) also bind to the IGF-1 receptor (IGF1R) to activate 
phosphor-inositol 3 kinase (PI3K). This binding brings the activity o f 
phosphodiesterase 3 (PDE3) to breakdown the cAM P (Eppig JJ et al., 2004). Also, 
insulin and IGF-1-induced Ras/C-Raf/MAPK pathway enhance and promote the 
progesterone-induced M os/MAPK pathway in MPF formation for GVBD in oocyte 
maturation resumption. By inhibiting R af / MAPK pathway, the anti-melanoma drug 
Vemurafenib demonstrates potential cytotoxicity on the maturing oocyte.
•  Before the LH surge, cAMP concentration within the pre-ovulated primary oocyte, is 
maintained at a high level. This high level o f cAM P maintains the activation o f PKA. 
which differs from functions o f  PKA in cumulus cells, inhibiting the early translation 
o f maternal mRNAs in the primary oocyte from maturation and causing prophase I 
G2 arrest. PKA also directly targets and phosphorylates Cdc25B, which sustains the 
catalytic effect o f  component o f MPF, the CDK1 (Cyclin-Dependent Kinase 1. also 
known as p34cdc2) (Gautier J et al., 1991). This high concentration o f  cAM P may be 
partially produced by the adenyl cyclase from the primary oocyte but dominantly 
delivered externally from gap junctions from surrounding cumulus granulosa cell 
projections (Downs & Eppig 1984, Downs et al. 1986). 3’, 5 ’-cyclic guanosine 
monophosphate (cGMP) from surrounding cumulus cells plays a similar role in 
increasing cAMP by inhibiting PDE3. The effect o f EGF in decreasing cGMP by the 
cumulus cell’s PDE leads to decrease o f cAMP. The dissociation o f gap junctions
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after the LH surge cuts o ff the cAMP supply and reinitiates oocyte meiosis 1 from G2 
arrest.
•  Cumulus cells mechanically stripping or chemically digesting the intercellular gap 
junctions allow the oocyte to resume its progress toward maturation. This recovery 
after the PMSG injection is critical for the ex vivo oocyte maturation resumption in 
the culture medium.
•  After reinitiating oocyte meiosis I, four stages o f maturation from GVBD until the 
start o f meiosis II include: (1) GVBD is initiated by phosphorylation o f  the nuclear 
lamins, which resemble the magnetic clips for the nuclear membrane integrity; (2 )
The nucleolus is completely dissolved; (3) The chromosomes are condensed by 
phosphorylation o f  the chromosome proteins, including histones; and (4) Barrel­
shaped meiotic spindle apparatus led by centrosomes are formed and polymerized 
All condensed chromosomes are aligned vertically along the center o f  the axis o f  the 
spindle barrel. All four stages events require the prerequisites o f successful GVBD, 
spindle apparatus formation, and correctly aligned chromosomes.
•  Extensive reversible phosphorylation and dephosphorylation maximize the success o f 
the progress from meiotic II through metaphase II arrest. Phosphorylation by kinases 
and dephosphorylation by phosphatases are the most important intracellular 
regulatory mechanisms in the primary oocyte. The cellular events o f  GVBD. spindle 
apparatus formation, and correctly aligned chromosomes are initiated by three 
principal kinases/phosphatases in the oocyte (1) Serine/threonine protein 
phosphatases (PP); (2) maturation promoting factor (MPF); and (3) MAPK pathway.
•  The involvement o f  serine/threonine protein phosphatases (PP) in the GV oocyte 
includes protein phosphatase-1 (PP1) and 2A (PP2A) (Smith GD et al., 1998). 
Inactivation o f MPF (p34cde2/cyclinB2) is positively regulated via tyrosine 
phosphorylation o f  p34cdc2 by PP2A during prolonged prophase arrest o f  the oocyte 
(Rime, H et al., 1995). The endogenous form o f PP2A also prevents progesterone- 
induced oocyte maturation (Iwashita, J et al., 1997). The PP1- and PP2A-inhibitor 
okadaic acid (OA) also demonstrates promotion o f oocyte meiosis resumption (Smith, 
G.D et al., 1998). The depletion o f  PP2A is sufficient to initiate oocyte maturation 
(Maton, G„ Lorca, 2005) and indicates blocking o f the meiotic spindle apparatus
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formation. Inhibition o f PP1 also leads to the nuclear envelop dissolution and 
complete GVBD.
•  Maturation promoting factor (MPF) (also known as mitosis-promoting factor or M- 
phase-promoting factor) is a heterodimer composed o f Cyclin B and p34cdc2 (CDK1). 
MPF strongly stimulates the meiotic activities by phosphorylating multiple target 
effectors required during oocyte meiosis resumption. MPF is undetectable in the GC- 
intact stage, gradually increases in GVBD, is peaks in metaphase I oocytes, and 
decreases in meiosis I anaphase and telophase (which dissembled and 
polyubiquitinated the Cyclin B by anaphase-promoting complex). However, MPF 
increases and stabilizes during secondary oocyte metaphase II arrest (Winston N et 
al., 1997).
•  In 1971, MPF microinjected into the cytoplasm o f progesterone-stimulated frog 
oocytes in G2 prophase I arrest stimulated resumption o f the maturation process 
(Masui Y, Markert CL, 1971). Activated MPF phosphorylates and activates (1) 
condensins and histones (HI and H3) for condensing the chromosomes; (2) various 
microtubule-associated proteins for the barrel-shaped spindle apparatus formation; 
and (3) lamins (lamin A, B and C) for the nuclear membrane depolymerization and 
dissolution (Maro B et al., 1994). Activation o f  the MPF plays a pivotal role in 
successful execution o f  the oocyte maturation events. For the activation o f MPF, the 
activated the p34cdc2 (CDK1) subunit must bind to Cyclin B for a complete functional 
unit. The threonine-161 (Thr-161) on the p34c(k2 (CDK1) must be phosphorylated by 
a Cyclin Activating Kinase (CAK). Threonine-14 (Thr-14) and tyrosine-15 residues 
o f the p34cdc2 (CDK1) must be dephosphorylated to be activated by the Cdc25. 
However. M ytl (W eel) continues to phosphorylate theTyr-15, which could have 
been inactivated by the Mos-MAPK pathway (Oh JS et al., 2010). PP2A must be 
inactivated to dephosphorylate the Cdc25 for the activation to occur (M asatoshi Hara 
et al., 2013).
•  The function o f the Mitogen-Activated Protein Kinase (MAPK) pathway will be
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discussed in section 1 .6 .
1.5 The Role of C-Raf in Normal Mouse Oocyte Development
Although Vemurafenib was developed against mutated B-RafV600E, its relevance is 
still valid in the normal ovum in relation to C -Raf as indicated by the binding data 
presented in section 1.2. During fetal development, mouse oocytes are arrested at the G2 
prophase stage o f  Meiosis I. At the onset o f  puberty, progesterone-induced meiosis 
maturation resumption is initiated by GVBD. GVBD is executed by the kinase activity 
o f MPF activation, which is a binding complex o f  Cyclin B and Cdc2 (Nurse et al.,
1998). The M ytl (W eel) is an inhibitor o f MPF complex in the Meiosis I G2 stage. 
M ytlis broken down by Ribosomal S6  Kinase (RSK) under direct activation o f 
extracellular signal-regulated kinase 2 (Erk2) (Palmer et al., 1998). The activation o f 
Erk2 by Mek 1/2 is followed by progesterone-induced Mos synthesis (Nebreda et al., 
1993; Sagata et al., 1988). The small inhibitor RNA (siRNA) for Mos mRNA 
significantly inhibits Mos accumulation and progesterone-induced GVBD (Sagata et al.. 
1988; Barrett et al., 1990). However, the inhibition will not completely block the 
downstream MPF activation after the initiation o f  progesterone stimulation (Fisher et al.,
1999). The fact that the MPF activation is not completely blocked indicates a secondary 
pathway working independently after Progesterone/Mos activation for complete 
activation o f  the MPF and the MAPK pathway. Meiotic resumption and GVBD has been 
shown to elicit insulin and IGF-1 via an RTK/Ras/C-Raf/Mek 1/2 pathway (Sudipta Paul 
et al., 2009). Blockage o f  Mos-induced activation o f Mek 1/2 in the insulin pre-treated 
oocyte demonstrated a delayed GVBD rather than an abrupt inhibition (Frederic et al.. 
2003) and the impairment o f the downstream Erk2 and RSK phosphorylation. However, 
at same time, the phosphorylation o f C-Raf is also partially inhibited (Frederic et al., 
2003).
At times the dominant-negative (DN) form o f C-Raf results in the impairment o f the 
Erk2 activation, Mos induced GVBD, and progesterone-induced meiotic maturation 
(Muslin et al., 1993). Furthermore, the DN form o f Erk2 causes the down-regulation o f
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C-Raf, whereas over-expression o f C -Raf at times accelerates GVBD progression 
(Shibuya et al., 1996).
A similar result is observed in maternal insulin-resistant mice where the mouse 
oocytes underwent oxidative stress. The resulting mitochondrial dysfunction led to 
impairment o f oocyte maturation and implantation failure (Xiang-Hong et al., 2012).
Mos is the only kinase phosphorylating M ekl, whereas complete R af phosphorylation is 
achieved by phospho-Erk2 (Bodart et al., 2005). Thus, the Ras/C-Raf/MAPK pathway 
acts as an important self-enhancing and self-promoting system.
Barrel shaped spindle apparatus formation and stabilization, correct chromosome 
alignment, and segregation during in both Meiosis I and Meiosis II divisions are the key 
indicators o f  healthy oocyte maturation (Eichenlaub-Ritter et al., 1986). Oocyte toxic 
compounds are more likely to cause chromosome non- disjunction, meiotic delay and 
aster star-like spindle formation (Eichenlaub-Ritter et al., 1988). The MAPK pathway 
plays a pivotal role in meiotic spindle apparatus formation and chromatin organization. 
The MAPK pathway has been proven to be involved in M icrotubule Organizing Center 
(MTOC) formation in mouse oocyte maturation (Verlhac et al., 1994). The same pattern 
o f  distribution has been observed for its downstream effector, RSK (Fan et al., 2003). 
Several studies have found that in the mouse oocyte, genetic knockouts along the MAPK 
pathway (like Mos, Erk2) showed a failure to achieve normal spindle assembly (Araki et 
al., 1996; Bodart et al., 2002; Choi et al., 1996; Zhao et al., 1991). Phosphorylation o f p- 
Rsk substrates, MAPK- interaction, spindle-stabilizing protein (MISS), and DOC1R in 
mouse oocytes are responsible for microtubule organization and morphogenesis 
(Lefebvre et al., 2002; Terret et al., 2003). The spatial co-localization o f MAPK with the 
metaphase spindle during meiosis I-to-II transition indicates a close relationship between 
them in mouse oocyte maturation (Hatch et al., 2001; Lee et al., 2000). Recent research 
shows that 75% MAPK activity causes a disturbed spindle with dispersed chromosomes, 
whereas 45% MAPK activity leads to a disintegrated spindle with scattered chromosomes 
(Wei Cui et al., 2012). This variable activity indicates the importance o f the C-Raf 
enhancing circuit in spindle formation (Wei et al., 2012). A developmental morphology 
assay was the best means to evaluate toxicity and quality control o f Vemurafenib on C- 
R af o f  the cumulus cell free oocyte collection after the PMSG stimulation (Ackerman et
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al., 1984). Spindle formation and chromosome alignment examined by IF staining as 
well as DNA integrity visualized by TUNEL assay were the best assays to demonstrate 
the consequences o f  oocyte C -Raf inhibition in oocyte maturation after Vemurafenib 
exposure (Negoescu A et al., 1998).
1.6 Normal Development of the Embryo
1.6.1 Embryo Development Stages and Morphological Changes
•  After fertilization: After approximately 16 to 18h after the oocyte fertilization
(sperm-oocyte fusion) and oocyte activation, the pronuclei are visible. The presence 
o f two pronuclei observed under light microscope is perceived as normal 
fertilization. The number, alignment, distributions, and orientation o f  pronuclei 
relative to polar bodies can be used as assessment standards for higher blastocyst 
formation and implantation rate. For normal zygote development, the chromosomes 
from each pronucleus are well-aligned in pairs on the newly formed spindle 
apparatus and are prepared for the first mitotic division. Timing for one cell embryo 
collection should follow the standard that two pronuclei must be clearly observable. 
Fang Wu et al. detailed a timeline from pronuclear stages to syngamy formation after 
hCG injection, finding that the optimal time for the fertilized one-cell collection fell 
between 26 and 30h post-hCG injection since at that time two pronuclei had reached 
their largest size(Fang Wu et al., 2008). The first mitotic division cycle seems to 
consume a longer time compared to its later divisions, averaging 16h more than the 
second division (Bolton, V. N. et al., 1984; Flach, G et al., 1982; Latham, K. E. et 
al., 1991). The transition from 1C to 2C appears to be the transition between 
maternal and embryonic gene expression. Maternal materials from oocyte 
cytoplasm provide the essential support for meiosis, fertilization and first mitosis and 
are degraded at the onset o f  2C stage (Braude. P et al., 1979; Pratt, H et al.. 1983). 
The two-cell block in some outbred strains has been observed because o f glucose
Figure 3. Developmental Stages of Normal and Abnormal Embryos
(A) Zygote embryo: Presence o f  two pro-nuclei with narrow perivitelline space and two 
small PBs
(B) 2 Cell Embryo (2 equal-sized blastomeres with narrow perivitelline space and two 
small PBs).
(C) 8  cell Embryo (8  equal sized blastomeres).
(D) Morula Embryo (cells begin to fuse: semi-circular cell outline with inner semi-circle 
fused together).
(E) Expanded blastocyst (cyst occupies 2/3 o f the zona pellucida enclosed area).
(F) Hatched blastocyst (Blastocyst begins to hatch out o f zona pellucida).
(G) Collapsed (deflated embryo after expansion).
(H) Fragmented (Frag: numerous and uneven-sized blastomeres or cytoplasmic blebs).
(I) Degenerated (condensed and granulated blastomeres).
18
inhibition. Gene expression o f  the embryo dominates the subsequent mitotic 
divisions (Flach, G et al., 1982). The embryonic genome expresses transcriptions at 
approximately 3h after G1 period (Poueymirou, WT et al., 1989; Latham. KE. et al., 
1991). The Ras/C-Raf/MAPK pathway plays an important role in this 1C to 2C 
transition (see section 1 .8 ).
•  Cleavage stages: In cleavage stages, embryo cells normally divide into 4 cells on 
Day 2 and 8  cells on Day 3, with equal-sized cells and no fragmentation. Before the 
morula stage, single cells, also called blastomeres, is omnipotent and can develop 
into an individual organism when separated from the zona pellucida-encircled 
compact morula. Fewer numbers o f cells in the corresponding days o f  the morula is 
considered as a developmental delay. Blastomere asymmetry, cytoplasmic 
inclusions, and blastomere multi-nucleation are all considered abnormal embryo 
development. The perivitelline space is squeezed into a very narrow space. The 
plasma membrane o f  blastomeres in the 8 -cell stage begins to be connected by the 
gap junction, which exchanges nutrients and signaling information.
•  Morula, blastocyst, and hatching stage: The eight-cell embryo begins to fuse 
together from the loosely-associated group cells on Day 3.5. The tight association o f 
cells compacted together forms the morula, named from the fruit “mulberry.” The 
cells continuously divide into approximately 30 cells in the zona pellucida. The 
failure o f compaction indicates a loss o f  viability. A fragmentation outside the cell 
compact is considered non-viable.
•  On the Day 4, the morula begins to differentiate to form a hollow space called 
blastocyst, which reaches 50-150 cells during the stage. The hollow cavity, or 
blastocoel, develops from a small chamber to an approximate 120 pM space. The 
embryo in this expanded space is called an expanded blastocyst. The outer layer o f 
the blastocyst is called the trophectoderm (TE); the inner layer is the inner cell mass 
(ICM). ICM cells are often considered as pluripotent stem cells. ICM can develop 
into any cell type (ectoderm, mesoderm or endoderm) and will later differentiate to 
cells forming various tissues, organs, or extra-embryonic tissues such as amnion and 
yolk sac. The TE on Day 6 , which further differentiates into cytotrophoblast and 
syncytiotrophoblast, the precursor components o f  the entire epithelial layer o f the
19
placenta (Knofler M, et al., 2001). Some o f the expanded blastocysts may be 
contracted or collapsed because o f the failure o f implantation in the medium culture. 
The collapsed blastocyst is a transient state which can be re-expanded once 
implanted (Keller G. et al., 2005). Deflating the blastocyst in vitrification becomes a 
common procedure in embryo cryopreservation.
•  On Day 6 , the expanded embryo hatches out o f zona pellucida (blastocyst hatching 
or embryo hatching). The embryo-derived plasminogen activator seems to be a 
proteolytic enzyme participating in the hatching process. The hatched embryo is 
irregular in its border and ready to implant in the uterus.
1.6,2 Molecular Biology of Embryo Development
From the sperm-oocyte fertilization to an embryo implanted in the uterus, many 
signaling pathways are involved in embryo development and differentiation. Each 
signaling pathway is responsible for one or several biological processes (e.g., cell growth, 
division, migration, apoptosis, and polarity). The signaling pathways in embryo 
development are an extremely complex network (Figure 9). Little is known about which 
pathways play a more dominant role.
•  MAPK pathways: Four MAPK pathways are involved in embryo development: (1) 
Ras/C-Raf (see section 1.8 ), (2) Jun N-terminal kinase (JNK), (3) p38 and (4) Erk5. 
The JNK and p38 MAPK pathways participate in the 8 C to blastocyst stage, while 
p38 is a filamentous actin regulator (Paliga AJ et al., 2008). JNK and p38 pathways 
are also required in blastocoel formation during its expansion, since the inhibition o f 
both pathways results in failure o f  cavity formation (Maekawa M et al., 2005).
•  Wnt signaling pathway: The W nt/p-catenin pathway is inactive until the blastocyst 
stage o f  embryo development. P-catenin is located in the nuclei o f the ICM. The 
dorsal side distribution o f  the P-catenin indicates that Wnt/p-catenin is involved in 
dorsal-ventral axis formation (Lloyd S et al., 2003).
•  PI3k/Akt pathway: The PI3K/Akt signaling pathway is responsible mainly for 
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Figure 4. The Complexity of Preimplantation Embryo Signaling Pathway 
Interactions
The signaling pathways (MAPK, PI3k/Akt, Wnt, Notch, and BMP) involved in 
preimplantation embryo are performing as a complex network. PI3k/Akt is also activated 
by Ras, which demonstrates that the growth-factor related growth signal could drive the 
anti-apoptotic signal, preventing programmed cell death. The Notch dominated 
differentiation signal can synchronize with the MAPK-dominated growth signal by 
sharing JNK/c-Jun effectors, whereas the direction o f the differentiation is the 
cooperative product o f the BMP, Wnt and Notch pathways. The entire embryo 
preimplantation development demonstrates a coordination o f the pathway network. Both 
must be present during the embryo development. The red-colored-solid lines indicate the 
pathways under a certain pathway family. The solid-arrowed lines indicate an direct 
effect towards the down-stream effector(s). The dash-arrowed lines indicate the indirect 
effect towards the down-stream effector(s).
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preimplantation embryos, the PI3K/Akt pathway suppresses programmed cell death, 
which could be quickly induced by the PI3k inhibitor (Gross VS et al., 2005). Akt 
inhibition can also lead to delay o f hatching in the preimplantation embryo (Riley JK 
et al., 2005).
•  The Notch signaling pathway: This pathway forces the cell to remain in the 
undifferentiated stage and prevents its developing into the subsequent stage or other 
alternative developmental stages (Hansson EM, et al.. 2004; Artavanis-Tsakonas S et 
al.. 1999).
•  The BMP signaling pathway: BMP belongs to the TGF-p superfamily and involves in 
polarity and spatial orientation development o f  the preimplantation embryo. This 
pathway is heavily involved in differentiation, regenerative processes, and axial 
formation (Zemicka-Goetz M et al., 2002).
1.7 The Role of C-Raf in Normal Embryo Development
The Ras/C-Raf/Mek MAPK pathway, which functions as the downstream effectors 
o f the FGF receptor and other Receptor Tyrosine Kinase (RTK) receptors, is one o f four 
MAPK pathways involved primarily in the early embryo and the post-implantation 
development (Yufen et al., 2005). Ras inhibitions by either siRNA, DN Ras, or Ras mAb 
halted the mouse embryo in early 2C stage. The fact that such blockage is completely 
recovered by constitutive transduction o f the C- R af molecule indicates that C -R af is the 
downstream effector o f Ras in embryo development (Yamauchi et al., 1994). Later 
experiments showed that phosphorylated C-Raf activation was found in the M-phase- 
specific cell cycle in early cleavage stage o f 2C embryos (Haraguchi et al., 1998). The 
2C stage, which acts as the critical reprogramming transition from maternal to embryonic 
gene transcription and expression pattern (Flach et al., 1982), is a particularly sensitive 
stage during embryo development (Goddard et al., 1983). Further, the Mek 1/2 and the 
Erk, downstream effectors o f the C- Raf, were shown to be expressed in the 
preimplantation embryo (Liu et al., 2004). The Erk inhibitor U0126-treated 2C embryos 
were reversibly arrested at G2/M transition to the 4-cell (4C) stage and the entire p-Erk- 
dependent gene expression pattern was altered (Maekawa et al., 2007).
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Figure 5. The Role of C-Raf in Normal Embryo Development
C-Raf plays an important role as a mediator in Ras MAPK pathway. The Ras MAPK 
pathway is involved in both pre- and post- implantation o f  embryo development. C-Raf 
is shown to be a key kinase in 1 cell to 2  cell transition and one o f six lethal mutations in 
the post-implantation stages FGF (Fibroblast Growth Factor); FGF-R (FGF Receptor); 
pRas (Phosphorylated Ras); p-C-Raf (Phosphorylated Raf); p-Mek 1/2 (Phosphorylated 
Mek 1/2); p-Erk (phosphorylated Erk); p-Rsk (Phosphorylated Rsk).
The same study pointed out that the arrested 4C embryo showed a looser cell-cell 
adhesion than did the control group. The resumption o f embryo development with 
normal 4-to-8 cell protein expression, driven by other pathways, was offset by adverse 
effects o f  loose cell adhesion and finally arrested at the 8 -cell (8 C) stage (M aekawa et al., 
2007). Active pC-Raf in embryonic day 2.5 showed a membrane localization, which 
indicates C -Raf activates the MAPK pathway from the cell membrane instead o f 
normally from nucleus (Wang et al., 2004).
On the other hand, preimplantation expression o f C-Raf also showed several critical 
influences on post-implantation development. Individuals with vascular defects, 
including those with placental vascular bed defects, died in middle-gestation because o f 
C-Raf deficiency in the embryonic stage (Wojnowski et al., 1997). Defects in placenta
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and liver were observed in embryos possessing C -Raf preimplantation deficiency (Mikula 
et al., 2001). Later research showed that B-Raf and C-Raf are two o f the six lethal null 
pre-implantation mutations resulting in the pre-implantation or placental lethality (Yufen 
Xie et al., 2005). Therefore, in this study, an ex vivo mouse embryo development study 
was initiated at the 1C stage to demonstrate potential pre-implantation toxicity. The p- 
Mek 1/2 in situ  IF assay for C-Raf kinase bioactivity was performed at 14h after the 1C 
embryo collection, the optimal time to observe the toxic effect o f  Vemurafenib on the C- 
R af expression in early embryo development.
1.8 The Vemurafenib in Pregnancy, Oocyte Maturation and Embryogenesis
The normal development o f the embryo and fetus is perceived as the critical factor 
in evaluating the toxicity o f any anticancer drug therapy. In the only case report available 
to evaluate the fetal toxicity o f Vemurafenib during pregnancy (Maleka et al., 2013). 
Maleka et al. found that a 37-year-old woman diagnosed with generalized stage IV 
melanoma initiated Vemurafenib therapy 960mg twice a day during her 25th week 
pregnancy after wide surgical excision and removal o f the sentinel node. She 
successfully delivered an infant via Caesarian section procedure at the 30th week o f 
gestation and died 3.5 months later with a relapse o f cerebral and dural metastasis.
During pregnancy, her melanoma mutated -B-RafV660E was determined and treatment o f 
9% intrauterine growth retardation (IUGR) had been initiated because o f tumor growth.
In rapid response to Vemurafenib, the new metastasis disappeared and lactate 
dehydrogenase reached to the normal line at one month o f  treatment. The patient 
complained o f the complications o f skin itches and exanthema, which disappeared one 
week after treatment. At the time o f delivery, IUGR reached 34% lower than the normal 
curve, indicating that the rapid response o f Vemurafenib did not correct but aggravate the 
IUGR. The infant received 10.9 pg/mL Vemurafenib drug transmitted through the 
umbilical cord, compared to 24.3 pg/mL in the patient. This result indicated a possible 
fetal toxicity o f  Vemurafenib. However, their report lacks further evaluation o f  the 
neurological development o f  the child. A 30th week premature baby case could not 
provide adequate testing for the safe use o f Vemurafenib in term for pregnancy and
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lactating mothers with MM. No risk o f congenital malformations can be ruled out if 
embryogenesis occurs after exposure to cytotoxic drugs. Also, childhood development 
data o f the fetus were not available to rule out certain specific cancer types (e.g.. 
squamous cell carcinoma and KA) resulting from Vemurafenib exposure. Data for fetal 
and/or childhood organ and systemic differentiations, development, and function were 
also unavailable. Finally, currently no available animal oocyte and embryotoxicity data 
exist for Vemurafenib, which is a new first line treatment drug for unresectable MM. 
Therefore, much research is necessary to evaluate the drug safety o f  Vemurafenib. In this 
study, toxicity tests were performed on the mouse embryo development and oocyte 
maturation upon the exposure to Vemurafenib.
1.9 Innovation
The present study was the first research testing Vemurafenib exposure on mouse 
oocyte maturation and embryo developmental teratogenicity and toxicities. This research 
contributes background knowledge o f  the drug Vemurafenib based on detailed data in 
developmental morphology, TC50 and cytogenic analysis. Since many additional studies 
will be necessary to ensure that Vemurafenib is free o f toxicity and teratogenicity, the 
current research serves as a reference for future studies on the detailed molecular 
mechanism o f oocyte and embryo toxicity. An understanding o f the effects o f 
Vemurafenib on the mouse oocyte and embryo will shed light on (1) further 
modifications o f  Vemurafenib by pharmaceutical companies to insure that oocytes and 
embryos are protected from toxicity and teratogenicity; (2 ) better therapeutic agent(s) 
combinations to reduce Vemurafenib toxicity and teratogenicity; (3) normal clinical 
applications on pregnant, lactating and potentially-pregnant patients with MM; and (4)
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unresolvable toxicological or teratogenic issues o f Vemurafenib.
1.10 Specific Aims
Aim 1: To determine the toxic developmental effects o f the anti-melanoma B- 
RafV600E inhibitor Vemurafenib on the ex vivo mouse oocyte (female gamete) maturation, 
GVBD, spindle formation, chromosomal alignment and DNA integrity.
W hile the anti-melanoma drug Vemurafenib principally inhibits mutated B-RafV600E 
in the MAPK signaling pathway, it also inhibits WT A-, B- and C-Raf monomers ex vivo 
(Bollag G, et al., 2010). However, Vemurafenib transactivates downstream Mek via 
drug-inhibited R af dimer in vivo (Poulikakos et al.. 2011). On the other hand, insulin-like 
growth factor-1 (IGF-1) induced Ras/C-Raf activation acts as a self-enhancing and self- 
promoting system in oocyte maturation including GVBD, spindle apparatus formation 
and chromosomal alignment (Kalma Y et al., 2004, Qing-Yuan Sun et al., 2009). Either 
activation or inhibition may cause significant adverse effects on later oocyte meiosis M il 
arrest formation. However, Vemurafenib toxicity on oocyte maturation is unknown. 
Therefore, mouse oocytes were stimulated and produced by an injection o f  pregnant mare 
serum gonadotropin (PMSG). Both female mouse ovaries were punctured, and oocytes 
were collected with cumulus cells stripped. Vemurafenib was directly exposed to 
cumulus-cell denuded oocytes at serial dilution from 0.01 pM to 100 pM.
Developmental morphology was analyzed by inverted microscopy from the GV-intact 
oocyte to GVBD to the Meiosis M il stage oocyte by evaluating the point o f  50% Toxic 
Concentration (TCso). Spindle formation and chromosomal alignment were analyzed by 
IF staining. DNA integrity o f the oocyte was visualized by the TUNEL assay.
Aim 2: To determine the effect o f anti-melanoma B-RafV600E inhibitor Vemurafenib 
on preimplantation embryo development when exposed ex vivo from the 1 C to hatching 
stages at the cellular level.
C -Raf plays an essential role in early 2C stage and post- implantation development 
in mouse embryos (Wang et al., 2004). Either activation or inhibition causes significant 
adverse effects in later embryonic and fetal development. Because the 1C stage embryo 
is considered to be vulnerable and sensitive to the surrounding environment, 1C mouse
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embryos were produced by a superovulating injection o f PMSG followed 48h later by an 
injection o f human chorionic gonadotropin (hCG). 1C embryos with two prominent pro­
nuclei were irrigated from oviducts excised after cervical dislocation (CD) euthanized 
plug-positive female mice between 26 to 30h post-hCG injection. Vemurafenib at 
concentrations from 0.01 pM to 100 pM were introduced into the culture medium for up 
to 11 Oh incubation period for this ex vivo experiment. Thus, Vemurafenib was directly 
exposed ex vivo to 1C embryos for the entire culture period. Cell development 
morphology was evaluated and TC50 was calculated. Embryo C -Raf bioactivity at the 
two-cell stage after drug exposure was semi-quantified by a p-Mek 1/2 in situ  IF assay.
Aim 3: To determine the effect at the cellular level o f the anti-melanoma B-RafV600H 
inhibitor Vemurafenib on preimplantation embryo development from 2C to hatching 
stages when the gamete was exposed in vivo in the dam ’s i.p. cavity injection before 
mating and embryo collection but not exposed to the drug after embryo collection.
This group o f superovulated mice was pre-injected in 7 doses i.p., with Vemurafenib 
(10 mg/kg) in vivo twice daily. The first injection was administered at 24-hour post- 
PMSG injection; the final dose was administered at 36-hour post-hCG injection).
Females were placed with a fertile male immediately post-hCG injection until a positive 
vaginal mucous plug was observed. Two-cell embryos were collected 42h post-hCG 
injection with the same procedure as in Aim 2. Two-cell embryos were then cultured in 
either a drug-free medium for either control, or the 10 mg/kg experimental Vemurafenib 
concentrations, and observed up to 96h after collection. Cell division and morphology 
were evaluated under inverted microscopy and a TC50 was calculated.
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Experimental Design
Determination o f  the toxicity o f the anti-melanoma B-Rafv600E inhibitor 
Vemurafenib to mouse oocytes and embryos provides an essential understanding for 
clinical physicians to benefit newly pregnant, lactating and potentially pregnant women 
with malignant melanoma (MM) who are urgently expecting and seeking effective 
medications. This novel research protocol also provides instructions for the physicians' 
prescriptions during their clinical practice as well as new directions for clinical 
researchers on the developmental evaluation, toxicity mechanism and combinational 
therapies for the drug. In order to test the hypothesis that Vemurafenib has detrimental 
effects on the oocyte maturation and/or embryo development, three major experiments 
were conducted as follows:
2.1.1 In vitro Oocyte Maturation Quality Control Assay
To determine the potential toxic developmental effects o f anti-melanoma B-RafV600E 
inhibitor Vemurafenib on ex vivo mouse oocyte maturation from (1) GV-intact oocyte to
(2) GVBD to (3) M il arrest, (4) spindle apparatus formation, (5) chromosomal alignment 
and (6 ) DNA integrity.
Experiment 1: Analysis o f  Vemurafenib toxicity on oocyte cell cycle progression during 
oocyte maturation resumption.
•  Morphological evaluation o f  the dose-dependent serial dilutions o f  Vemurafenib 
toxicity on mouse oocyte maturation progression.
•  Determination and evaluation o f  the TC?o and the effect o f  Vemurafenib on mouse 
oocyte maturation progression.
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Experiment 2: Spindle formation and chromosome alignment IF Staining:
•  Morphological and cytogenic analysis o f spindle apparatus formation and 
chromosomal alignment were performed after exposure o f  Vemurafenib serial 
dilution.
Experiment 3: TUNEL assay for DNA integrity:
•  DNA integrity o f oocytes after Vemurafenib exposure was examined by DNA 
TUNEL assay for detecting oocyte DNA fragmentation.
2.1.2 Ex vivo 1C Mouse Embryo Development Quality Control Assay
To determine the effect o f Vemurafenib on the embryo development from 1C to 
preimplantation hatching stage at cellular and subcellular levels o f ex vivo embryos by 
the mouse embryo toxicity assay.
Experiment 1: Analysis o f  Vemurafenib toxicity with pre-implantation embryos on cell 
cycle progression during embryo development.
•  Morphological evaluation o f  dose-dependent serial dilutions o f Vemurafenib toxicity 
on mouse embryo development progression to the hatching (H) stage.
•  Determination and evaluation o f the TC50 and the effect o f Vemurafenib on mouse 
1C embryo development to H stage.
Experiment 2: Semi-quantification o f the Embryo C-Raf bioactivity by p-M ek 1/2 in situ  
IF assay.
•  Determine the overall C-Raf bioactivity o f  the 2C embryos after exposure to 
Vemurafenib.
2.1.3 In vivo Mouse Embryo Development Quality Control Assay
To determine the in vivo effect o f anti-melanoma B-RafV600t inhibitor Vemurafenib 
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Figure 6. Experimental Design Flow Chart
In order to test the potential toxicities o f  Vemurafenib exposure on mouse gam etes and embryos, ex vivo oocyte m aturation and 
quality control assay was performed for morphology, immunofluorescence and TUNEL. The ex vivo  1C mouse embryo 
developmental and quality control assay was performed for morphology and p-M ek 1/2 IF to assess toxicity after V em urafenib 
exposure. The in vivo mouse embryo assay took place with the pre-injection o f  Vemurafenib to mimic the actual clinical use 
o f Vemurafenib. Morphological evaluation o f  the 2C embryo was examined.
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exposed in vivo in the dam 's i.p. cavity before mating and embryo collection but not 
exposed to the drug after embryo collection.
•  Determination o f  in vivo therapeutic dose (10 mg/kg) effects o f Vemurafenib on the 
overall mouse embryo development from oocyte maturation to embryo H stage.
1.2 Animals
The female B6CBAFi/J mice (C57B6 male/CBA female, both inbred) (Jackson 
Laboratory, Bar Harbor, ME, USA) were used in all experiments. The male CD1 outbred 
mice (Charles River Laboratories, Wilmington, MA, USA) were paired for mating in 
both in vitro and in vivo mouse embryo developmental assays. Animal health is critical 
for optimal reproductive results. Mice must not be stressed by constant exposure to noise, 
wet bedding, improper light cycle, or extreme temperature fluctuations. Upon arrival in 
the animal facilities o f the Innovation Research Park Building 2 (IRP-2) at Old Dominion 
University, no more than five female mice were placed per cage with a minimum o f 97 
cm2 floor area per animal and 13 cm height. The male mice were housed individually in 
similar caging. Purina 5001 laboratory rodent diet and water were freely accessible and 
provided ad libitum. Room temperature was maintained between 22-24°C (~74F), with 
14 hour light/10 hour dark natural cycle for experiments which matches our exogenous 
hormonal superovulation timeline.
2.2.1 Justification of Animal Use
•  Mouse oocyte and embryo developmental cultures are exquisitely sensitive to toxic 
compounds, chemicals and drugs. (Ackerman et al., 1984).
•  The female B6CBAF]/J and male CD1 mouse strains (see section 2.2.2) are a well- 
established and commonly paired animal model for mouse oocyte maturation and 
embryo developmental quality control tests with a large volume o f publications.
•  Mouse oocyte maturation and embryonic development up to pre-implantation stage 
closely reflects the corresponding stages o f  the human embryo and can predict the 
successful in vivo fertilization (IVF) o f  the human embryo.
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•  The superovulation method in this paired mouse model produces a large collection o f 
oocytes and embryos per female mouse significantly reducing the number o f animals 
consumed by sequential PMSG and hCG hormonal stimulating injections.
•  This work, begun in 1980, is a continuation o f research on oocyte maturation and 
embryo developmental toxicity using the mouse model.
Experiments and animal use protocols were approved by the Institutional Animal 
Care and Use Committee (1ACUC) (Assurance 13-011) at Old Dominion University. 
Euthanization by cervical dislocation (CD), approved by the American Veterinary 
Medical Association (AVMA), was used to eliminate the confounding factors o f CO2, 
Na-pentobarbital, isoflurane or other compounds during embryo and oocyte collection.
No carefully-crafted simulator could mimic the cooperative complexity o f  oocyte 
maturation and embryo developments and differentiation that occurs in the biological 
whole-animal model. No cell culture, computer program, invertebrate or other lower 
species could substitute for the mouse oocyte and embryo toxicity test.
2.2.2 Justification of the Animal Selection
Consistent mouse strain use is important to the success o f assays conducted in the 
laboratory. Embryos from different strains behave differently during culture. Culture 
conditions that are ideal for one mouse strain or combination o f  pure strains may not be 
acceptable for different purposes. An animal strain is considered an inbred strain when it 
has been maintained by brother with sister mating or offspring with parent mating for a 
minimum o f 20 consecutive generations. The result is a genetically defined strain nearly 
homologous in every way, aside from the difference o f sex chromosome contribution.
The B6CBAF]/J strain o f mouse is the hybrid result o f breeding two different inbred 
mouse strains (CBA/J males and C57B6/J (B6) females). The coat color o f these animals 
is agouti. The strain designation for male stud mice used in all experiments was CD1. an 
outbred albino mouse (ICR) strain.
Consistency o f animal strains is essential to the uniformity o f assay results. Because 
females o f a hybrid strain are crossed with CD1 males from an outbred strain, embryos o f 
this inbred/outbred cross are unpredictable and completely unsuitable for further use. If a
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plug-negative female is actually pregnant, the offspring should be removed and 
euthanized prior to reproductive competency. Because embryos from our chosen mating- 
pair hybrid strain (B6CBA F j/J crossed with CD1) do not exhibit the 2C block in 
development, these embryos can be used in both the 1C and 2C stages which gives us 
some control over embryo variability throughout all experiments in this study.
2.2.3 Animal Mating Conditions
Generally, weanling animals at four weeks o f  age have the best oocyte and embryo 
production. Stud males must be a minimum 9 weeks o f  age before being placed into 
service and may require several trial matings before producing high-quality embryos. 
Non-plugged superovulated female mice were put into separate cages and recycled for 
use after two weeks’ rest. An individual female mouse superovulated more than three 
times without having a positive plug was removed from the colony and euthanized by CD. 
Males failing to mate over four consecutive opportunities were removed from the colony 
and euthanized by CD. Both strains over 10 months in age were removed from the 
colony. Successful mating will produce vaginal plug rates ranging from 70-100 percent 
and oocyte and embryo production will average 20 and 25 respectively per female.
These figures will vary in relation to stability o f the animal facility, quality o f the 
hormone, age and health o f the males and females, seasonal timing, and strain o f mouse 
used, as well as other lesser factors. Reconstituted hormones can be reliably stored at - 
20°C for approximately 12 months without significant reduction in biological potency.
2.3 Reagent Preparation
2.3.1 Vemurafenib Solutions
Ex vivo mouse oocyte maturation and embryo developmental assays with 
Vemurafenib 100X stock solution and in vivo 10 mg/kg mouse embryo assay injection 
solutions were prepared.
According to the FDA drug evaluation and research report, both crystalline solid and
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form II Microprecipitated Bulk Powder (MBP) o f  Vemurafenib has poor aqueous media 
solubility at 37°C o f less than 0.26 mg/lOOOmL and thus a low bioavailability. While 
preparing the solutions, white insoluble particles formed in modified Krebs bicarbonate- 
buffered medium (mKBB) or M l6 medium due to this insoluble characteristic was 
precipitated at the bottom o f each well during culture in the 96-well Falcon sterile culture 
plate (Cat No. 353072, Fisher Scientific). Heating to 56°C and stirring the mKBB or 
M l 6-Vemurafenib particle mixture did not increase solubility o f  the drug. Filtering a 200 
mL lot through a 0.22 pm filter unit (Nalge NUNC) to remove any microorganism 
contamination during solution preparation caused complete blockage o f a white particle 
film on the filter. The final concentration o f the drug was lowered and varied from well 
to well, which did not reflect the actual potential toxicity or teratogenicity o f the drug and 
significantly decreased the authentication o f  test result. In polar dimethyl sulfoxide 
(DMSO), a sterile liquid solvent, the dissolvability o f  Vemurafenib reaches nearly 98 
mg/mL. When DMSO is placed in the culture media up to 2% v/v concentration it shows 
no significant change in the survival rate with cultured embryos. One caveat is that 
DMSO is a potent stress proteins inducer (Hallare A et al., 2006). Ten mg Vemurafenib 
powder was dissolved in 204 pL o f sterile DMSO (Sigma) and sequentially dissolved in 
204 mL o f mKBB or M l 6 medium with a final concentration o f  100 pM /L (100X) with 
0.1% DMSO as stock solution. M l6 and mKBB media both have penicillin and 
streptomycin supplement, but the solution preparation procedure took place in a laminar 
flow hood to guarantee solution sterility. The 100X stock solution o f Vemurafenib was 
serially diluted 1:10 for the lower concentrations in both ex vivo oocyte maturation and 
1C embryo development assays. One mL o f the higher concentrated solution was mixed 
with 9 mL o f mKBB or M l 6 medium to make the lower concentration solutions. For the 
in vivo mouse embryo assay, the 10 mg/kg Vemurafenib stock solution was made by 
sequentially dissolving 10 mg Vemurafenib into 8 pL DMSO and then into 8 mL mKBB 
or M l6 solutions. The maximum volume for mouse i.p. injection was 200 pL per 
injection and the solution was cloudy without being fully dissolved. During dilution
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procedures, vortexing was used to assure the final concentration at the lower doses.
2.3.2 Modified Kreb’s Bicarbonate Buffer (mKBB) Medium, Microtubule 
Stabilizing Buffer (MTSB) and Immunofluorescence Blocking Buffer Preparations
•  The mKBB medium preparation (Ackerman, S et al., 1983): The mKBB was
Table 1. Components of the mKBB Medium (400 mL)
Components Cat. No. Volume (g) Final Concentration (mM)
NaCl S5886, Sigma 2.1996 94.0900 mM
KC1 P5405, Sigma 0.1424 4.7800 mM
CaCl2.2H20 C7902, Sigma 0.1008 1.9200 mM
KH2P 0 4 P5655, Sigma 0.0644 1.1800 mM
M gS 04 M2643, Sigma 0.0572 1.1900 mM
N aH C 03 S5761, Sigma 0.8436 25.1100 mM
DL-Lactate L4263, Sigma 1.6 mL 3.3 pL/mL
Sodium Pyruvate P2256, Sigma 0.0220 0.5000 mM
D-(+)-Glucose G7021, Sigma 0.4000 5.5500 mM
BSA (fraction V) A4503, Sigma 1.6000 4.0000 mg/mL
Pen/Strep (5k IU) P0781, Sigma 4.0 mL 50.0 IU/mL
prepared fresh each month by using the formula in Table 1. Each new batch o f 
medium was tested using the 2C mouse embryo assay to reach at least 85% passing 
rate. A Mettler analytical balance (Model No B214825957, Mettler) and stir bar 
were used with constant stirring while adding ingredients to approximately 150 mL 
o f Milli-Q deionized water in the listed order on the preparation formula. After 
adding all dry and wet ingredients, including BSA, to the mixture was stirred until
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the protein was fully dissolved. The medium was transferred into a 200 mL Class A 
volumetric flask for final volume by adding water up to the 200 mL line.
This medium was subjected to filtration through a 500 mL, 0.22 pm Nalgene 
filter. The first three filtration passes used approximately five milliliters as a filter 
rinse before filtering the remainder for use. The initial 10-15 mL rinse fluid was 
used for osmolality and pH measurements. The medium pH was between 7.7 and 
8.0 as measured by Mettler SevenCompact pH meter Ion S220 (Serial No.
B2026211682, Mettler). The osmolality was between 270 and 300 mOsm/kg H2O 
(Advanced* model 3250 single-sample, freezing point depression osmometer). If 
the osmolality was above 300 mOsm/kg H2O it was brought down according to the 
following formula:
„ JmOsm, - mOsmj) „ T,
V  2 % V I
mOsm,
Where the mOsmj = the initial osmolality; mOsmj -  the desired osmolality; V ] = 
volume o f the medium sample, and V2 = the volume o f  the medium to be removed 
then replaced with the same amount o f H20  respectively.
Table 2. Microtubule Stabilizing Buffer (MTSB) Preparation (100 mL)
Components Cat. No. Volume Final Concentration
PBS P5493, Sigma 97 mL IX
PIPES P6757, Sigma 3.02400 g 100.0000 mM
MgCl2 M8266, Sigma 0.02605 g 5.0000 mM
Triton X-100 X I00, Sigma 1.0 mL 1.0%
Formaldehyde F8775, Sigma 2.0 mL 2.0%
EGTA E3889, Sigma 0.09506 g 2.5000 mM
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•  For embryo culture, the protein supplement mirrors the human plasma physiology 
which is approximately 4 mg/mL. This protein supplement reduced the adhesive 
characteristic o f oocytes and embryos, blocked the electrical charges on the outer 
surface o f the cells and provided a secondary source o f amino acids. While 
performing experiments, all media was overlaid with toxicity-negative light mineral 
oil. The oil provided a physical barrier to prevent the medium from evaporation with 
osmolality increase. Oil also increased the time o f CO2 equilibration so mKBB and 
M l6 media were pre-incubated at least 24h before each experiment, M2 medium 
was HEPES-buffered and did not need the 24-hour pre-incubation. Media were not 
kept in incubator more than 3 days due to ammonia accumulation from protein 
breakdown.
•  The MTSB solution preparation: The MTSB solution for the oocyte fixation and 
permeation in the ex vivo oocyte maturation assay was prepared in accordance to 
Table 2 (Eichenlaub-Ritter, U, 1986, 1989; Soewarto, D et al., 1995). Fixation and 
permeation is the key step in stabilizing the depolymerization process o f  the spindle 
apparatus. EGTA acts as the chelating agent for blocking calcium related 
bioactivities like apoptosis. Triton X-100 permeates the unfixed (or lightly fixed) 
oolemma and decreases the surface tension o f the MTSB solution during IF staining. 
Formaldehyde cross-links and denatures the cytoplasmic and nuclear proteins, 
including histones, and chromosomal DNA. The pH was adjusted by PBS to the 
final volume.
•  IF blocking buffer preparation: Blocking buffer was prepared according to Table 3 
for blocking the reactive antigens and reducing the background stain in the IF 
staining process. Universal blocking o f the mouse-derived miscellaneous antigens 
was accomplished with mouse serum, BSA and non-fat dry milk. And the sodium 
azide is bacteriostatic, stopping bacterial growth. The pH was adjusted by PBS to
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Table 3. IF Stain Blocking Solution (100 mL) (Liu, L et al., 2002)
Components Cat. No. Volume Final Concentration
NaN3 S2002, Sigma 0.0200 g 0.0200%
Triton X-100 X I00, Sigma 0.01 mL 0.01%
Glycine 50046, Sigma 0.75070 g 100.0000 mM
Mouse Serum M5905, Sigma 2.0 mL 2.0%
Non-Fat Dry Milk M7409, Sigma 0.2000 g 0.2000%
BSA A4503, Sigma 2.0000 g 2.0000%
PBS P5493, Sigma 97.99 mL IX
Table 4. Component Differences Between M16 And M2 Media in g/L




k h 2p o 4 0.162 0.162
M gS 04 0.1649 0.1649
N aH C 03 2.101 0.35
DL-Lactate 2.95 2.95
Sodium Pyruvate 0.0363 0.0363
D-(+)-Glucose 1 1




2.3.3 Difference of M16 and M2 Media
Both M l6 (Cat No. M7292, Sigma-Aldrich) and M2 (Cat No. M7167, Sigma-Aldrich) 
media are the most commonly used media for in vitro culture for oocyte maturation and 
pre-implantation embryo development. The difference o f the composition is shown in 
Table 4.
Both o f them contain the components o f  modified Krebs-Ringer bicarbonate buffered 
medium, which is very similar to W hitten’s medium. Both M2 and M l6 include lactate 
and pyruvate which is benefit for the early stage o f  the embryo development since 
embryo in this stage does not utilize glucose efficiently, whereas the M2 medium is the 
modified version o f the M l 6 medium by substituting some sodium bicarbonate with 
HEPES buffer which is an intracellular phosphate buffer. Therefore, M l6 medium is 
suitable for the CO2 incubator culture to mimic the true fallopian tube environment. M2 
is suitable for extended operations and procedures outside the incubator like oocyte 
recovery and 1C embryo collection. Both o f them add phenol red as the indicator for pH 
change and are stored in the refrigerator.
2.4 Toxicity of Vemurafenib on Ex Vivo Oocyte Maturation and Quality
While gametes and embryos in childbearing mothers with the B-Raf mutated MM 
would have a very low probability o f  having a simultaneously mutated C-Raf, the mouse 
gametes and embryos without the mutation successfully circumvent the development 
retardation bias caused by the malignancy cachexia while testing drug toxicity.
Therefore, a mouse without this mutation in gametes and embryos should be an accurate 
model for determining the drug’s toxicity. Female BsCBAFi/J mice were chosen for 
their continuity o f 1C to 2C transition without blockage which excluded the blockage 
bias caused by other mouse strains. Oocyte follicular growth was over stimulated by the 
PMSG and primary oocytes were recovered by puncturing the large antral follicles. 
Cumulus cells were gently striped away. Denuded oocytes with an intact GV were
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collected and tested in different concentrations o f Vemurafenib. The control group was 
treated exactly like experimental groups but without Vemurafenib. Since the 
Vemurafenib could only be dissolved in the DMSO with 0.1% final concentration, a 
control group with 0.1 % DMSO medium solution was simultaneously tested. After 16h 
culture, the number o f  GV intact, GVBD, M il arrested and fragmented/degenerated 
oocytes were recorded. TC50 was calculated. Oocyte cellular and subcellular levels o f 
cell morphology were analyzed by IF staining on spindle formation and chromosomal 
alignment. Also, the DNA integrity was visualized by TUNEL assay. Experiments were 
run in triplicate.
2.4.1 Mouse Oocytes Recovery Procedure
Eight female B^CBAFi/J mice (Jackson Laboratory) 4-week-old to 6 -month-old 
were i.p. injected with 0.1 mL (5 IU) PMSG (Cat. No. G4877, Sigma -Aldrich) to 
stimulate the ovarian follicular growth. After 48h post-injection, mice were euthanized 
by cervical dislocation (CD). The ovaries with fat pads were carefully removed with 
sterile scissors and watchmaker forceps (Cat. No ST-JFC-7, ASSI). The ovaries were 
transferred to a 35 mm petri-dish (Cat. No 134738, NUNC) with 3 mL o f M2 medium 
(Cat. No. M7167, Sigma-Aldrich) supplemented with penicillin/streptomycin 120 U/mL 
(Cat. No P4333, Sigma-Aldrich) pre-warmed in a Nuaire AutoFlow NU-4750 W ater 
Jacket C 0 2  Incubator (Cat No NU4750, Nuaire). The M2 medium was overlaid with 2 
mL o f toxicity negative mineral oil to prevent the osmolality change from water 
evaporation. Under a Zeiss Discover V 8  Stereo Dissecting M icroscope (Serial No.
3911005189, Zeiss), the large antral follicles were punctured through by using a lm L  
syringe (Cat. No. 02G088A, Norm-Ject) with 30-gauge/'/2-inch needle (Cat. No. 305106, 
B-D). Oocytes were either (1) gently aspirated in and out o f a Stripper® (Cat No. 
MXL3-STR, Origio) to strip o ff the surrounding cumulus cells. The denuded oocyte with 
the intact GV (Diameter = 70~80um) were collected and transferred to the M2 medium. 
Nude oocytes found before stripped by micropipettes were discarded for the possible 
maturation prior collection because o f  the loss o f the inhibitory cumulus
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cells maintaining the G2 prophase arresting state.
2.4.2 Denuded Oocytes Cultured with Various Vemurafenib Concentrations
Vemurafenib was dissolved in the sterile DMSO (Cat No D8418, Sigma-Aldrich) 
and sequentially added to the M l 6 medium to a final concentration o f 100 pM/L in 0.1% 
DMSO, as the stock solution. The Vemurafenib serial dilutions in each well was created 
by a serial dilution ratio o f  1:10 producing lO pM /L , 1 pM/L, 0.1 pM /L, and 0.01 pm/L 
concentrations. To maintain blind evaluation o f data by Investigator I, Investigator II 
dispensed and coded the different concentration solutions into two 4-well Falcon dishes 
(Cat No. 08-772-IB, Fisher Scientific) without identifying the codes. Denuded oocytes 
from each mouse were assigned into wells containing a final volume o f 0.8 mL mKBB 
medium with each serial dilution o f  the Vemurafenib. One control oocyte group was 
cultured with 0.8mL o f mKBB medium without Vemurafenib. The other control oocyte 
group was cultured with 0.8mL mKBB in 0.1% DMSO. All oocytes were cultured for 
16h at 37°C; 5% CO2; and 100% humidity. Both experimental and control oocyte groups 
were assigned to wells in 20 min intervals to ensure that oocytes were synchronously 
developed in each well, which accounted for the handling time interval.
2.4.3 Oocyte Development Morphological Evaluation
After 16h in vitro culture, the number o f  oocytes from the lowest to highest 
developmental stages in all groups were counted and evaluated. Four developmental 
stages were defined as the following: (1) GV: Oocytes with an intact GV and prominent 
nucleolus are arrested at the Meiosis I G2 prophase stage o f the cell cycle; (2) GVBD,
MI: The meiotic resumption which oocytes experience with GV disintegration in 
Metaphase o f  meiosis I; (3) MH-arrest: Oocytes progress to M il arrest o f meiosis II after 
expelling the first polar body (PB1). (4) Fragment (Frag): Various and uneven-sized
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Wash 3 times bv PBS
Transfer in wash buffer
1 ml rinse buffer for wash
Immunofluorescence Assay TUNEL Assay
Wash 3 times by PBS
Two 4-well Falcon plates Re-suspend the cells by 500 pi PBS
Wash & blocking by 
Immunofluorescence Blocking Buffer
Various stages o f oocyte after 16h 
culture in Incubator
Various stages o f oocyte after 16h 
culture in Incubator
One droD o f the SlowFade® Gold Antifade Reauent with DAPI
Oocvtes transferred to ethanol ore-cleaned slides
200pl MTSB in 37°C water bath 30 
min
Examined &Evaluated by Zeiss A1 Axio Inverted Fluorescence M icroscope
50 pi o f each sample: 10 pi reaction 
buffer, 0.75 pi o f  TdT enzyme, 8 pi 
Br-dUTP and 31.25 pi dH20  37°C 3h
Add 100 pi Ab solution (95 pi rinse 
buffer+ 5 pi Alexa Fluor 488 
conjugated anti-Br-dU Ab) 30 min
Fixed by sequential 5 mL 1% 
Formaldehyde in PBS 15 min, 2% 
Triton X-100 and 70% Ethanol 30 min
100 pi Alexa Fluor 488 conjugated 
mouse monoclonal anti alpha-tubulin 
Ab at 45 -60  min, 37°C
Figure 7. The Flow chart of IF and TUNEL assay
The staining procedure conducted was classical direct immunofluorescence staining. 
TUNEL assay procedures were followed through Life Technologies APO-BrdU™  
TUNEL Assay Kit manual instruction.
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Table 5. Oocyte Developmental Stages Definition
Stages Definition
GV Oocytes with an intact germinal vesicle and prominent nucleolus are 
arrested at the Meiosis I G2 prophase stage o f the cell cycle.
GVBD or The meiotic resumption which oocytes experience with GV disintegration in
MI Metaphase o f  meiosis I.
MH-arrest Oocytes progress to M il arrest o f  meiosis II after expelling the first PB.
Frag. Fragmented: Various and uneven-sized cytoplasmic blebs.
Deg. degenerated: condensed and granulated blastomeres
cytoplasmic blebs. Investigator II decoded the concentrations after IF staining, and 
recording o f  data by Investigator I. The TC50 is defined as a Vemurafenib concentration 
at 16h which (1) inhibits 50% o f the oocytes from showing a metaphase plate or 
expelling the first PB; (2) causes DNA damage, (3) shows disoriented spindle formation; 
and/or (4) shows chromosome misalignment. Nontoxic concentration (NC) is defined as 
a lack o f statistical difference on oocyte maturation to meiosis II arrest upon exposure to 
Vemurafenib compared with the control group. Normally, at least 85% o f the oocytes 
will extrude the first PB within 16h culture in an in vitro control group (Eichenlaub- 
Ritter. U, 1995). Four developmental stage images were captured through a Zeiss Vert 
A1 Axio inverted research microscope fitted with a Zeiss AxioCam ICml camera unit 
(Cat. No. 426113, Zeiss). Oocytes images o f each stage were photographed with an Axio 
Version Special Edition 64 bit Release 4.9.1 software (Zeiss).
2.4.4 IF Staining and Microscopy for the Cytological Analysis
Vemurafenib-exposed oocytes and two control group oocytes progressing to GVBD 
with PB (meiosis II arrest) or without PB (meiosis I arrest) were stained in separate wells 
o f two 4-well Falcon plates through direct tubulin and chromosome IF labeling to
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examine the spindle formation and chromosome alignment. The entire staining 
procedure was conducted at room temperature unless otherwise specified. Oocytes were 
fixed and permeated in each well 30 min in a 37°C water bath by a 0.8 mL Microtubule- 
stabling buffer (MTSB) (Eichenlaub-Ritter, U, 1986, 1989; Soewarto, D et al.. 1995).
The oocytes were then washed and blocked in a 4°C moist chamber overnight by a 
blocking solution (Liu, L et al., 2002). Oocytes were washed in a 0.8 mL PBS and 
incubated in darkness with 200 pL o f  Alexa Fluor 488 (Ex/Em =495/519 nm) conjugated 
mouse monoclonal anti alpha-tubulin antibody (1:20~1:40 PBS, Cat No. 322588, Life 
Scientific) 45-60 min in a 37°C water bath. Oocytes were washed in a 0.8 mL PBS and 
transferred to ethanol pre-cleaned slides. One drop o f the SlowFade® Gold Antifade 
Reagent with DAPI (Cat No. 36939, Life Scientific) was added to each slide in darkness 
for 15-20 min or overnight at 4°C for chromosome staining. Slides were examined under 
a Zeiss Vert A 1 Axio inverted fluorescence microscope using a combination o f  two filter 
sets: (1) DAPI filter (Cat No. 49000, Chroma Technology) (Ex/Em=345/455) for the 
chromosome alignment visualization and (2) FITC/ Alexa Fluor 488/Fluo3/Oregon Green 
filter (Cat N o.49011, Chroma Technology) (Ex/Em=495/519nm) for spindle apparatus 
formation visualization. Images were taken by Axio Version Special Edition 64 bit 
Release 4.9.1 software. The number o f  oocytes with either normal or abnormal spindle 
formation or aligned or disordered chromosomes was recorded in each treated and control 
group.
2.4.5 Terminal Transferase dUTP Nick End Labeling (TUNEL) Assay
Morphologically normal chromosomal alignment and spindle apparatus formation is 
not sufficient and conclusive for stating that DNA is intact without damage during 
Vemurafenib exposure. The TUNEL assay is a common method for detecting DNA 
fragmentation which results only from apoptotic signaling cascades. Therefore, potential 
apoptosis after Vemurafenib exposure was measured by the TUNEL assay. 
Vemurafenib-exposed oocytes and two control group PC oocytes progressing to GVBD 
with PB (M il arrest) or without PB (MI arrest) were subjected to a DNA TUNEL assay 
analysis. Procedures were carefully followed through the APO-BrdU™  TUNEL Assay
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Kit manual instruction (Cat No. A23210, Life Technologies) (Figure 13). Oocytes were 
transferred among a Sigmacoat-coated 4-well Falcon dish to avoid sticky oocytes after 
the wash step. For the final step, one drop o f SlowFade® Gold Antifade Reagent with 
DAPI (Invitrogen) was added to the slides without light for 15-20 min or 4°C overnight 
instead o f the propodium iodide in the kit for chromosome staining. Slides were 
examined under a Zeiss Vert A 1 Axio inverted fluorescence microscope using a 
combination o f two filter sets: (1) DAPI filter (Ex/Em=345/455) for the chromosome 
alignment visualization and (2) FITC/Alexa Fluor 488/Fluo3/Oregon Green filter 
(Ex/Em =495/519nm) for the DNA damage visualization. Images were taken by an Axio 
Version Special Edition 64 bit Release 4.9.1 software. Since oocyte is composed o f only 
one cell and its polar body is perceived as internal positive control. So the TUNEL assay 
stained oocytes were observed individually. The number o f oocytes with either intact or 
damaged DNA or aligned or disordered chromosomes were recorded in each treated and 
control groups.
2.4.6 Statistical Analysis
Because oocyte stages, spindle formation, chromosome alignment, and DNA integrity 
results are considered as discrete data, both oocyte morphology and cytogenic 
examination results were evaluated by one-way ANOVA test via SPSS v.21 to determine 
whether a significant difference exists among groups. A p value<0.05 was considered 
statistically significant. (*p < 0.05, **p < 0.01, ***p < 0.001).
2.5 Toxicity of Vemurafenib on E x  Vivo 1C Mouse Embryo Development and 
Quality
M ouse embryo growth and development from 1C to blastocyst hatching upon 
exposure o f toxic compounds has been considered the most reliable methodology for 
quality assurance/quality control (QA/QC) since 1984 (Ackerman S et al., 1984; Tucker 
KE et al., 2004). Embryos exposed to various concentrations o f  Vemurafenib were
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obtained by irrigating oviducts from CD-euthanized female mice after PMSG/hCG 
injection with mating. Embryo development from 1C to hatching blastocyst were 
evaluated morphologically at 38, 62, 86, and 1 lOh after culture. Tests were repeated in 
triplicate.
2.5.1 Superovulation and Mating
Four-week to seven-month-old female Bf,CBAF|/J mice were superovulated by 0.1 
mL (5 IU) i.p. injection o f  PMSG followed by an i.p injection o f 0.1 mL (5 IU) hCG 48h 
later using a 1 mL-syringe with a 30 gauge/Vi inch needle (Hogan B et al., 2002). Each 
female mouse and one young fertile CD1 male mouse were placed together in a single 
cage for mating. Mating normally occurs within 6h. After 16h post-hCG injection mated 
female mice were examined through the vagina for a coitus mucous plug.
2.5.2 Embryo Collection
Plug-positive female mice were euthanized by CD between 26 and 30h after hCG 
injection. The skin o f  the mouse was pulled on the upper end and lower end to produce a 
sterile surgical field, free o f hair and contaminants. A V-shaped incision was made on 
the abdominal musculature to pull upward and expose the xiphoid process. The small 
intestine was pushed to one side to expose the uterus. Tubal scissors were used to pierce 
the membranes under the uterus to cut the ovarian ligament. A slight amount o f traction 
was maintained on the uterine horn so that the oviduct was torn off. And the uterine horn 
was stretched to the xiphoid process and the oviduct was excised from the uterine hom on 
the uterine side. After both oviducts had been harvested from each mouse, all oviducts 
containing embryos were freed and transferred into 3 mL pre-warmed equilibrated 
mKBB culture medium supplemented with 0.4% BSA (pH 7.6-7.8) (Ackerman, S et al., 
1983) in a sterile 35-mm Nunclon culture dish. The medium was sterilized by filtering 
through the 0.22 pm filter unit (Nalge Co) and successfully pre-tested to determine 
toxicity. To be considered non-toxic, more than 75% o f the embryos were required to 
pass over at least the morula stage. 1C embryos were flowed out from the oviducts by
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using a 30 gauge needle connected to an mKBB medium filled lm L  syringe through 
fimbria (Swanson, R et al., 1992) under a Zeiss Discover V8 Stereo Dissecting 
Microscope.
2.5.3 Embryo Culture with Vemurafenib at Different Concentration
Vemurafenib was first dissolved in sterile DMSO, and then dissolved in an mKBB 
medium with a final concentration o f 100 pM with 0.1% DMSO as the stock solution. A 
Vemurafenib serial dilution was created by serial dilution at a ratio o f  1:10 to 10 pM /L, 1 
pM/L, 0.1 pM /L and 0.01 pM/L. Each o f  the two negative control groups were 
incubated with a solution o f  either: (1) 200 pL mKBB with 0.1% DMSO or 200 pL 
mKBB medium without Vemurafenib. The positive control was treated with a mixture o f 
0.0000025% Zephiran Chloride with mKBB. For the blind evaluation o f  data by 
Investigator I, Investigator II coded and dispensed the various concentration solutions 
into rows in a 96-well Falcon sterile plate (Cat No 08-772-17, Fisher Scientific) without 
identifying labels. Depending on the number o f embryos in each mouse, additional plates 
were used. All embryos from one mouse were transferred into a single row with one 
embryo per well. One row represented one replicate on any one experimental day. Two 
pro-nuclei with a narrow perivitelline space and two small PBs were visible in each 
morphologically-acceptable 1C embryo. All embryos were cultured in a 37°C incubator 
with 100% humidity and a 5% CO2 Air supplement.
2.5.4 Embryo Development Evaluation
All embryo developmental stages were defined as in Table 5. The numbers o f 
embryos in each stage from lowest to highest development were recorded and 
morphologically evaluated at 38, 62, 86, and 11 Oh o f culture using a Zeiss Vert A l Axio 
inverted research microscope fitted with a Zeiss AxioCam ICm l camera unit. Embryo 
images at each stage were captured by an Axio Version Special Edition 64 bit Release
4.9.1 software. Investigator I recorded the results; Investigator II decoded the 
concentrations afterward. TC50 was defined as the Vemurafenib concentration that
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inhibited 50% o f embryos progressing to 2C, 4C, morula, blastocyst, and hatching stages 
at 38, 62, 86, and 11 Oh o f culture respectively compared with the control group; while 
negative control was designated as no statistical difference on embryo development with 
exposure to Vemurafenib. Positive control was designated as the presence o f  a statistical 
difference on embryo development with exposure to Vemurafenib.
2.5.5 The Ex Vivo 1C Embryo p-Mek 1/2 In Situ IF Staining for Embryo C-Raf 
Activity
Twenty embryos o f  all concentrations after 14h culture, regardless o f
Table 6. Embryo Developmental Stages Definition
Stages Definition
1C presence o f two pro-nuclei with a narrow perivitelline space and two small PBs
2C 2 equal sized blastomeres with a narrow perivitelline space and two small PBs
3-4C 3-4 cell: 3-4 equal sized blastomeres with a narrow perivitelline space
5-6C 5-6 equal sized blastomeres with a narrow perivitelline space
7-8C 7-8 equal-sized blastomeres with a narrow perivitelline space
cM cells begin to fuse: semi-circular cell outline with inner semi-circle fused
M morula cells fully fused
eB early blastocyst: cyst formation begins
nB normal blastocyst cyst: occupies half o f the zona pellucida enclosed area
EB expanded blastocyst: cyst occupies 2/3 o f the zona pellucida enclosed area
hB hatched blastocyst: Blastocyst begins to hatch out o f zona pellucida
H fully Hatched: Blastocyst fully hatches out o f  zona pellucida
Deg degenerated: condensed and granulated blastomeres
Frag fragmented: numerous and uneven-sized blastomeres or cytoplasmic blebs
Col collapsed: deflated embryo after expansion
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developmental stages (1C, 2C or Frag./Deg.), were subject to embryo p-M ek 1/2 in situ  
IF Staining for embryo C -Raf activity. The entire staining procedure was conducted at 
room temperature unless otherwise specified. Embryos were fixed in 2% 
paraformaldehyde for 20 minutes and permeated in each well 5 minutes with 2% Triton 
X-100. The embryos were then washed and blocked at least 4h with a blocking solution 
(Liu, L et al., 2002). Embryos were washed in PBS in wells incubated with lm L 1:100 
rabbit anti-phospho-M ek 1/2 (Ser 217/221) Antibody (Car. No. 912IS, Cell Signaling 
Technology) overnight. Embryos then were washed with PBS in wells and incubated 
with 1:40 PBS biotinylated Goat Anti-Rabbit secondary antibody (Cat. No. 65-6140, Life 
Technologies) in 37°C for at least 2h. Embryos were then washed in PBS in wells again 
and transferred to ethanol pre-cleaned slides and incubated with Alexa Fluor 488 
(Ex/Em=495/519 nm) conjugated streptavidin (Car. No. S-l 1223, Life Technologies) in 
darkness for 30 minutes. Then slides were added one drop o f SlowFade® Gold Antifade 
Reagent with DAPI (Cat No. 36939, Life Scientific) was added to each slide in darkness 
for 5 minutes for chromosome staining. Slides were examined under a Zeiss Vert A l 
Axio inverted fluorescence microscope using a combination o f two filter sets: (1) DAPI 
filter (Cat No. 49000, Chroma Technology) (Ex/Em=345/455) for chromosome 
alignment visualization and (2) FITC/ Alexa Fluor 488/Fluo3/Oregon Green filter (Cat 
No.49011, Chroma Technology) (Ex/Em =495/519nm) for Mek 1/2 phosphorylation. 
Images were taken by an Axio Version Special Edition 64 bit Release 4.9.1 software.
2.5.6 Statistical Analysis
Developmental stage scoring ranged from -1 to 5 points: -1 for degenerated (Deg.) or 
fragmented (Frag.); 0 for 2C; 1 for 3-4C; 2 for 5-8C; 3 for morula; 3.5 for collapsed 
blastocyst; 4 for blastocyst and 5 for hatching. Each row was calculated by the mean 
rank o f scores. Scores represent a continuous type o f  data for multiple means with single 
variables. However, because the parametric assumptions for normal distribution and 
equal number o f samples could not be satisfied, the One-way analysis o f variance 
(ANOVA) by Kruskal-W allis rank test was performed via SPSS v.21 to determine the 
developmental difference between the groups. For the same reason, the Mann-W hitney
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test with Bonferroni adjustment test was used as the follow-up test between treated and 
control groups. The pvalue<0.05 was considered as statistically significant (*p <0.05,
**p <0.01, ***p <0.001). Because embryo stages are considered as the discrete data, a 
one-way ANOVA test was applied to embryo development in different embryonic stages.
2.6 Toxicity of Vemurafenib on In Vivo Mouse Embryo Development and Quality
Ex vivo assays used to analyze advanced molecular biochemical and cytogenic 
mechanisms do not mimic the actual in vivo environment and precise responses to drug 
exposure. For example, on Day 7 after zygote formation, the cell number o f  the 
blastocyst in in vitro development is 125 ±19, whereas the in vivo development cell 
number is 186 cells. This phenomenon indicates that embryos collected and cultured in 
an in vitro medium were delayed by one day.
In the in vivo test, superovulated mice were pre-injected with 7 doses i.p. o f  
Vemurafenib (10 mg/kg) twice daily. The first injection was given 12h after the PMSG 
injection; the last dose was administered 36h after the hCG injection). The long half-life 
(57h) o f the drug and 12 hour delay injection strategy maximized the length o f  time o f 
drug exposure to the embryo. The regimen o f 10 mg/kg o f  the drug dissolved in DMSO 
and injected i.p. with 100 pL PBS has been successfully tested by Richard C. Koya et al. 
as the normal therapeutic dose o f Vemurafenib. Although accurate measurement o f  the 
drug serum concentration could not be assured because o f technical limitations, the direct 
opening o f  mouse oviducts into the abdominal cavity at their fimbriated end provided an 
accurate exposure o f the drug at the injected concentrations. Both 0.1 % DMSO and 
negative control mice were also injected in the same manner. After hCG injection 48h 
post-PMSG injection, each female mouse was placed with a fertile male until a positive 
vaginal mucous plug was observed post-mating. 2C embryos were collected ex vivo as 
the standard o f 2 equal sized blastomeres with narrow perivitelline space and two small 
PBs. Embryo collection from all mice followed the same operational procedure and 
qualified standards as described in section 2.5.2 (control groups and Vemurafenib 
injected groups). Embryos were transferred into 96-well Falcon sterile plates and coded 
by Experimenter II. Experimental (10 mg/kg) and negative controls (plain control and
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0.1%DMSO control) were incubated with 200pL mKBB medium without Vemurafenib 
in a 5%C02 incubator culture with 100% humidity. Cell division and morphology were 
evaluated under a Zeiss A l Axio inverted microscope. Results were recorded by 
Investigator I and decoded by Investigator II for further TC50 calculation and statistical 
analysis. The remaining experimental procedures, morphological evaluations and 




3.1 Ex Vivo Oocyte Maturation Quality Control Assay
3.1.1 Cytological Morphology Evaluation of Cell Cycle in Control Ex Vivo Oocytes
GV-intact oocytes were isolated from sexually mature female mice by puncturing 
follicles. Collected oocytes were cultured with the anti-melanoma drug Vemurafenib in 
various concentrations to test its potential toxicity and teratogenicity. By stripping off the 
cumulus granulosa cells, the majority o f GV-intact oocytes would experience GVBD in 
2h, observed under a Zeiss A l inverted microscope. The majority o f  control cells 
progressed to M il stage characterized by extrusion o f  the first polar body. Only a few 
oocytes were incompetent to progress to M il metaphase stage and were arrested in either 
GV-intact, MI prophase stage or Frag./Deg. (Table 7).
3.1.2 The Progression of Cell Cycle of Oocytes in the Presence of Vemurafenib
Normal oocyte development after LH stimulation will undergo GVBD, progressing 
from G2 GV-intact resting stage to MI stage and then to the M il-arrested stage. Normal 
morphological developmental stages were defined as follows: (1) GV: Oocytes with an 
intact GV and prominent nucleolus arrested at meiosis I G2 prophase stage o f the cell 
cycle; (2) GVBD or MI: meiosis resumes and oocytes experience GV disintegration in 
metaphase o f meiosis I; (3) M il arrest: Oocytes progress to M il arrest by extruding the 
first polar body (PB 1) and having a metaphase plate structure. (Figure 8) To detect the 
Vemurafenib morphological toxicity on oocytes, a one-way ANOVA test o f  oocyte 
maturation was evaluated. One-way ANOVA results showed a significant difference 
among groups o f  Vemurafenib serial dilution after 16h o f  culture compared to 0.1% 
DMSO and negative control groups. In follow-up statistical tests, concentrations at or 
below
Figure 8. The Normal Morphological Developmental Stages of the Oocyte
(A) GV: Oocytes with an intact GV are arrested at Meiosis I G2 prophase stage o f  the 
cell cycle (400x).
(B) GVBD: The meiosis resumption oocytes experience GV disintegration in Metaphase 
I (400x).
(C) M il arrest: Oocytes progress to M il arrest o f  the meiosis II after extracting the first 
polar body (400x).
the therapeutic concentration did not appear to be significantly different compared to 
control groups in maturation stages (Table 7). The majority o f oocytes from 1 pM to the 
0.1% DMSO control successfully progressed to the MH-arrest stage and all oocytes in the 
negative control group progressed to the MH-arrest stage. Only a few oocytes in these 
groups were confined to GV-intact, MI and Fragmented/Degenerated stages. However, 
the concentration o f  10 pM and 100 pM showed a significant difference from the control 
groups [11 ± 1 (73% ± 7%), p =0.014] and [4 ± 2 (29% ± 10%), p < 0.001] versus [14 ± 1 
(95% ± 4%)] at MH-arrest stage oocytes respectively (Table 7). The difference showed 
that the majority o f  oocytes were incompetent to mature into MH-arrest stage. Most 
oocytes in the 100 pM group were arrested at the MI stage [5 ± 2 (36% ± 10%) versus 0 
± 1 (2% ± 4%) at MI stage]. Fragmentation and degeneration could also be seen in this 
group. The 100 pM group’s pattern was similar to the positive control group which
Table 7. Triplicate Evaluation o f ex vivo Oocytes at 16h Development in Vemurafenib Solutions
Groups Replicate Mean of the Number of Oocytes ±SD (Mean o f Percentage ±SD)
Number GV GVBD, MI Mil Frag/D eg
Positive Control* 3 2 ± 1 (13 ±  7)** 6 ±  1(43 ±6)*** 3 ±  1 (18 ±  4) *** 4 ± 1 (25 ± 5)***
Negative Controlb 3 0 ±  1 (2 ± 4) 0 ±  1(2 ± 4 ) 14 ± 1 (95 ± 4) 0 ± 0 ( 0 ± 0 )
0.1 % DMSOc 3 1 ± 1 (5 ±  4) 0 ± 0 ( 0 ± 0 ) 13 ± 2  (90 ± 9 ) 1 ± 1 (5 ± 4)
100 pMd 3 3 ±  1 (18 ± 4)** 5 i  2 (36 ± 10)*** 4 ± 2 (29 ± 10) *** 3 ± 1 (18 ± 4)***
10 pMd 3 1±  1 (9 ± 3 ) 2 ±  1(13 ± 7 ) 11 ± 1 (73 ±  7)* 1 ±  1 (5 ±  4)
1 pMd 3 1 ± 1 (7 ±  7) 1 ±  1 (9 ± 3) 13 ± 1 (84 ±  8) 0 ± 0 ( 0 ± 0 )
0.1 pMd 3 1 ± 1 (5 ± 4) 1 ±  1 (5 ± 4) 13 ± 1 (91 ± 4 ) 0 ± 0 (0 ± 0)
0.01 pMd 3 0 ± 0 ( 0 ± 0 ) 1 ± 1 (9 ± 3) 13 ± 1  (91 ± 4 ) 0 ± 1 (2 ± 4)
*** Highly significantly different from negative control, p < 0.001.
** Significant difference from negative control, p < 0.01
* Significant difference from negative control, p < 0.05
a. Positive Control: composed o f 0.0000025% Zephiran Chloride with modified Kreb’s Bicarbonate Buffer (mKBB), which 
has proven gemmate.'cmbryo toxicity.
b. Negative Control: mKBB without DMSO.
c. 0.1 % DMSO: DMSO dissolved in mKBB at a final concentration of 0.1 % as DMSO control.
d. Serial dilution: Serially diluted from 100X stock solution made by Vemurafenib dissolved in DMSO and subsequently in 
mKBB to reach the concentration of 100 pM Vemurafenib 0.1% DMSO mKBB. And each concentration was adjusted to 
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Figure 9. Concentration-Dependent Response of Oocyte Maturation
Concentration related response by percentage o f  oocyte maturation (GV, GVBD, M il and 
Frag/Deg shown) after 16h in presence o f Vemurafenib is shown. The concentration o f 
10 u M and 100 u M showed a significant difference from the control groups [11 +  1 
(73% ±  7%), p =0.014] and [4 +  2 (29% ±  10%), p ^  0.001] versus [ 1 4 + 1  (95% +  
4%)] at MH-arrest stage oocytes respectively. Positive Control: composed o f 
0.0000025% Zephiran Chloride with modified Kreb’s Bicarbonate Buffer (mKBB), 
which has proven gemmate/embryo toxicity. Negative Control: mKBB only without 
DMSO. 0.1% DMSO: DMSO dissolved in mKBB as final concentration o f  0.1% as 
DMSO control.
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produced a clear oocyte toxic effect (p < 0.001).
3.1.3 Spindle Apparatus and Chromosome Alignment Shape in Oocytes in the 
Presence of Vemurafenib after 16h of Culture
Abnormal morphological change leads to abnormal spindle formation and 
chromosome alignment. However, normal morphology in oocytes arriving at the MII- 
arrest stage does not guarantee that the spindle apparatus and chromosomes are formed 
and aligned correctly to support future fertilization and embryonic life.
The Alexa-flour 488 fluorescent dye conjugated anti-tubulin antibody directly 
stained the microtubules a bright green color and the DAPI stained chromosomes were 
blue. Immunofluorescent images o f  oocyte spindle formation and chromosomes were 
taken and evaluated after 16h culture with Vemurafenib. GV-intact ova had no 
microtubules to evaluate but their chromosomes could be scattered in an unordered 
pattern. The spindle fibers and chromosomes o f the polar body were usually disturbed 
and unaligned, even in controls, due to depletion o f ATP compared to the oocyte. With 
higher concentrations o f Vemurafenib (10 pM or 100 pM), the following normal and 
damaged spindle apparatus and chromosome organization is shown in Figure 15: (1) 
barrel spindle and aligned chromosome in MH-arrest oocyte; (2) misaligned spindle and 
unaligned chromosome in MH-arrest oocyte; (3) barrel spindle and aligned chromosome 
in MI oocyte; (4) barrel spindle and unaligned chromosome in MI oocyte; and (5) 
misaligned spindle and unaligned chromosome in MI oocyte. With 1 pM, 0.1 pM and 
0.01 pM o f Vemurafenib, 0.1% DMSO control, and negative control groups, most o f the 
oocytes could proceed to MH-arrest with barrel-shaped spindle apparatus and equator - 
aligned chromosomes (Figure 8). Interestingly, both intact and misaligned spindle fibers 
could be found in unaligned chromosome MI oocytes which indicated the MI spindle 
could be formed without correct chromosomal alignment. A disturbed spindle apparatus 
could produce complete chromosomal disorientation which indicated that successful 
chromosomal alignment relies on the guidance o f  barrel shaped spindle fibers. 
Chromosomal abnormalities could not predict the outcome o f spindle shapes.
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Figure 10. Oocyte Responses of Spindle Formation and Chromosome Alignment 
after 16h Vemurafenib Exposure
(A, B and C) from one cell, A, M il; B, Barrel shaped spindle; C, aligned chromosome. 
(D, E and F) from one cell, D, M il; E, Misaligned spindle; F, unaligned chromosome. 
(G, H and I) from one cell, G, MI; H, Barrel shaped spindle; I, unaligned chromosome 
Concentration related response o f  spindle apparatus formation and chromosome 
alignment (GV, GVBD, and M il) after 16h in the presence o f Vemurafenib. Figures 
showed the immunofluorescence staining o f different responses o f oocytes under the 
influence o f  Vemurafenib. MI = Metaphase I; M il = Metaphase II. Cell was taken by 
phase. Spindle fiber was stained as green and chromosomes were stained as blue.
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Figure 10. (Continued): Oocyte Responses of Spindle Formation and Chromosome 
Alignment after 16h Vemurafenib Exposure
(J, K, and L) from one cell, J, MI; K, Barrel shaped spindle; L, aligned chromosome.
(M, N, and O) from one cell, M, MI; N, Misaligned spindle; O, unaligned chromosome. 
(P, Q, and R) from one cell show P, GV; Q, no spindle fibers; R, unaligned chromosome. 
Concentration related response o f  spindle apparatus formation and chromosome 
alignment (GV, GVBD, and M il) after 16h in the presence o f Vemurafenib. Figures 
showed the immunofluorescence staining o f different responses o f  oocytes under the 
influence o f Vemurafenib. MI = Metaphase I; M il = Metaphase II; GV = Germinal 
Vesicle intact. Cell was taken by DIC phase. Spindle fiber was stained as green and 
chromosomes were stained as blue.
Table S. Triplicate Analysis o f Spindle Apparatus Morphology and Chromosomal Alignment in Oocytes 16h Post-
Vemurafenib Treatments
Groups Replicate Mean Number of Oocytes ±SD (Mean Percentage ±SD)
Number Normal Spindle Abnormal Spindle Normal Chrom. Abnormal Chrom.
Positive Control* 3 4 ± 3 (25 ± 19)*** 11 ± 3  (75 ± 19)*** 1 ± 1 (5 ± 8)*** 14 ± 1 (95 ±8)***
Negative Control*1 3 14 ± 1 (95 ± 4 ) 1 ± 1 (5 ± 4) 14 ± 1 (95 ± 4) 1 ± 1 (5 ± 4)
0.1 % DMSOc 3 14 ± 1 (91 ± 8) 1 ±  1 (9 ± 8 ) 14 db 1 (91 ± 8 ) 1±  1 (9 ±  8)
100 pMd 3 7 ± 3 (46 ± 16)*** 8 ± 3 (54 ± 16)*** 3 ± 1 (28 ±  13)*** 12 ± 1 (72 ± 13)***
10 pMd 3 14 ± 1 (69 ± 9) 4 ±  1(31 ±9)*** 7 ± 0 (47 ± 0)*** 8 ± 0 (53 ± 0)***
1 pMd 3 14 ± 0 (9 3  ± 7 ) 1 ± 0 (7 ±  7) 13 ± 1 (87 ± 7 ) 2 ± 1 (13 ±  7)
0.1 pMd 3 14 ± 1  (93 ± 0 ) 1 ± 1 (7 ±  0) 13 ± 0 (87 ± 0) 2 ± 0 (13 ± 0)
0.01 pMd 3 12 ± 4  (95 ± 4 ) 0 ± 0 (5 ± 4) 13 ± 0 ( 8 9  ± 3 ) 2 ±  1 (11 ± 3 )
*** Highly significantly difference from negative control, p < 0.001
a. Positive Control: composed of 0.0000025% Zephiran Chloride with modified Kreb’s Bicarbonate Buffer (mKBB), which
has proven gemmate/embryo toxicity.
b. Negative Control: mKBB without DMSO.
c. 0.1%DMSO: DMSO dissolved in mKBB ata final concentration o f 0.1% as DMSO control.
d. Serial dilution: Serially diluted from 100X stock solution made by Vemurafenib dissolved in DMSO and subsequently in 
mKBB to reach the concentration of 100 pM Vemurafenib 0.1% DMSO mKBB. And each concentration was adjusted to 
maintain the final DMSO concentration to 0.1%
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According to the statistics, after 16h o f culture with Vemurafenib, the 100 pM 
concentration showed a highly significant difference from control groups. This mirrored 
the morphological pattern (p < 0.001). The 100 pM Vemurafenib caused 8  ± 3 (54% ± 
16%) aberrant spindle formations and a majority (72% ± 13%) o f chromosomal 
misalignments (Table 8 ). However, the concentration 1 pM or below, which is the 
therapeutic concentration and below, showed no significant difference from control 
groups in spindle apparatus formation. Almost all oocytes progressed to the MH-arrest 
stage with barrel shaped spindle fibers and correctly aligned chromosomes.
The 10 pM concentration o f  Vemurafenib which was morphologically normal 
compared to control groups became significantly different in chromosomal alignment 
when compared to control groups (p < 0.001). 8  ± 0 (53% ± 0%) oocyte chromosomes 
misaliged (p = 0.0009) after 16h 10 pM Vemurafenib exposure. Besides GV-intact, MI 
and Frag./Deg. oocytes, the morphologically normal M il-arrested oocytes with 
abnormalities o f  the spindle formation and chromosome alignment contributed to another 
31% ± 6 % weight to the actual incompetency o f MH-arrest oocytes after 10 pM 
Vemurafenib culture. Similarly, 24% ± 11% actual incompetency was added to the 
morphologically normal M il-arrested oocytes in thelOO pM Vemurafenib group. In all 
results combined, 100 pM Vemurafenib showed a highly significant difference than the 
control groups (p < 0.0001), in which 82% ± 4% o f oocytes were incapable o f further 
events such as fertilization, early embryo formation and implantation. Similar to 100X 
Vemurafenib, a significant statistical difference (p 0.001) was found in 10 pM, in 
which 53% ± 9% o f the oocytes were incapable o f  further developmental events. All 
other groups showed no difference from the 0.1% DMSO and negative control groups. 
TC50 is considered as 10 pM,
Table 9. Triplicate Analysis o f Spindle Apparatus Morphology and Chromosomal Alignment in GVBD/MI and MH- 
Arrest Oocytes 16h Post-Vemurafenib Treatment
Groups Replicate Mean Number of Oocytes ±SD (Mean Percentage ±SD)
Number MI (Barrel, Aligned) All Other MI Mil (Barrel, Aligned) All Other M il
Positive Control* 3 0 ±  1 (3 ± 6 ) 6 ±  1 (12 ± 7) 0 ±  0 (0 i  0 )* ** 3 ±  1 (32 ±  11)***
Negative Control1* 3 0 ± 0 ( 0 ± 0 ) O i l  (4 ± 2 ) 14 ±  1 (98 ±  4) 0 ± 0 ( 0 ± 0 )
0.1 % DMSOc 3 0 ± 0 ( 0 ± 0 ) 0 ±  1 (5 ±  3) 13 ± 2  (97 ± 5 ) 0 ± 0 ( 0 ± 0 )
100 pMd 3 1 ± 1 (7 ±  6) 1 ±  1 (10 ± 6 ) 3 ± 1 (28 i  7 )* ** 2 ±  1 (24 ±  11 )***
10 pMd 3 0 ±  1 (2 ±  4) 1 ± 0 (4 i  2) 7 ± 1 (54 ±  11)*** 4 ±  1 (31 ± 6 ) * * *
1 pMd 3 1 ±  1 (5 ±  4) 0 ±  0 (0 i  0) 13 ±  1 (90 ±  4) 0 ±  1 (2 ± 4 )
0.1 pMd 3 0 ± 0 ( 0 ± 0 ) 1 ±  0 (4 ±  2) 13 ± 0 (9 5  ± 4 ) 0 ± 0 ( 0 ± 0 )
0.01 pMd 3 0 ±  0 (0 ±  4) 0 ± 0 ( 0 ± 0 ) 13 ±  1 (91 ± 4 ) 0 ±  1 (2 ± 4 )
*** Highly significantly difference from negative control, p < 0.001
a. Positive Control: composed of 0.0000025% Zephiran Chloride with modified Kreb’s Bicarbonate Buffer (mKBB), which
has proven gemmate embryo toxicity.
b. Negative Control: mKBB without DMSO.
c. 0.1% DMSO: DMSO dissolved in mKBB at a final concentration o f 0.1% as DMSO control.
d. Serial dilution: Serially diluted from 100X stock solution made by Vemurafenib dissolved in DMSO and subsequently in 
mKBB to reach the concentration of 100 pM Vemurafenib 0.1% DMSO mKBB. And each concentration was adjusted to 
maintain the final DMSO concentration to 0.1%
Table 10. Triplicate Overall Results o f Morphology, Spindle Apparatus Shape and Chromosome Alignment in 
Oocytes 16h Post-Vemurafenib Treatment
Groups Replicate Mean Number of Oocytes ±SD (Mean Percentage ±SD)
Number MII-Arrest, Barrel Spindle, Aligned Chromosome All Other Stages
Positive Control* 3 0 ± 0 ( 0 ± 0 ) * * » 15 ± 1 (100 ±0)***
Negative Control 3 14 ± 1 (98 ±  4) 0 ±  1 (2 ± 4)
0.1 % DMSOc 3 13 ± 2  (90 ± 9 ) 1 ± 1 (10 ± 9)
100 pMd 3 3 ±  1 (18 ±4)*** 12 ± 1 (82 ± 4)***
10 pMd 3 7 ± 1 (47 ± 9)*** 8 ±  1 (53 ± 9)***
1 pMd 3 13 ± 1 (84 ± 8 ) 2 ± 1 (19 ± 2)
0.1 pMd 3 13 ± 0 ( 8 9  ± 3 ) 2 ± 1  (11 ± 3 )
0.01 pMd 3 13 ± 1 (91 ± 8 ) 1±  1 (9 ±  8)
*** Highly significantly difference from negative control, p < 0.001
a. Positive Control: composed o f 0.0000025% Zephiran Chloride with modified Kreb’s Bicarbonate Buffer (mKBB), which
has proven gemmate'embryo toxicity.
b. Negative Control: mKBB without DMSO.
c. 0.1% DMSO: DMSO dissolved in mKBB at a final concentration o f 0.1% as DMSO control.
d. Serial dilution: Serially diluted from 100X stock solution made by Vemurafenib dissolved in DMSO and subsequently in 
mKBB to reach the concentration of 100 pM Vemurafenib 0.1% DMSO mKBB. And each concentration was adjusted to 
maintain the final DMSO concentration to 0.1%
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whereas NC is 1 pM.
3.1.4 The DNA Integrity of Oocytes in the Presence of Vemurafenib
Similar to spindle formation and chromosome alignment, abnormal morphological 
change does not lead to intact DNA. However, normal morphological changes in oocytes 
to the MH-arrest stage are not sufficient to conclude that the DNA is free o f  massive 
damage caused by the drug. Barrel-shaped spindle apparatus and correct spindle equator- 
aligned chromosomes cannot guarantee intact DNA either. However, this experiment 
showed similar result patterns as the spindle formation and chromosome alignment.
The Alexa-flour 488 fluorescent dye conjugated anti-Br-dU antibody indirectly stained 
the Br-dUTP labeled nick end caused by DNA damage provided an easily identifiable 
bright green color. The blue DAPI stained chromosomes provided the reference for 
corresponding DNA damage labeling. Immunofluorescent images o f TUNEL assay 
results photographed after 16 hour culture o f  Vemurafenib were evaluated under a Zeiss 
A1 inverted fluorescent microscope. Generally, GV-intact after 16h culture o f 
Vemurafenib without any progress in development always possessed DNA massive 
damage. Also, the DNA in the polar body was usually damaged because o f  the scarcity 
o f an energy source compared with the oocyte. Except for GV-intact oocytes, other 
combinations o f morphological appearance and DNA integrity could be shown in higher 
concentrations o f  Vemurafenib (10 pM or 100 pM ) (see Figure 16): (1) TUNEL negative 
DNA intact M il arrest oocyte; (2) TUNEL positive DNA damaged MH-arrest oocyte; (3) 
TUNEL positive MI oocyte. Most o f the oocytes in the 0.1% DMSO control group, 
negative control groups and 1 pM, 0.1 pM, 0.01 pM o f Vemurafenib formed MH-arrest 
oocytes with a DNA intact negative TUNEL effect (Table 11). All GV and MI oocyte 
polar bodies, whether the oocytes were from control group or in 100 pM group, showed 
clear DNA damage after 16h culture o f Vemurafenib. Based on the statistical results, the 
100 pM Vemurafenib showed a highly significant difference from the control groups, 
which showed a pattern similar to the morphological evaluation (p < 0.001). The 100 pM 





Figure 11. Oocyte Responses of DNA Integrity after 16h Vemurafenib Exposure
(A, B, and C) from one cell A, M il stage; B, aligned chromosome; C, TUNEL negative. 
(D. E, and F) from one cell D, M il stage; E: unaligned chromosome; F, TUNEL positive. 
(G, H, and I) from one cell G, MI stage; H: unaligned chromosome; I, TUNEL positive. 
Concentration related response o f  DNA integrity (GV, MI, and M il) after 16h in presence 
o f  Vemurafenib. Figures showed the TUNEL immunofluorescence staining o f different 
responses o f  oocytes under influence o f the Vemurafenib. MI: Metaphase I; MIL 
Metaphase II. Cell was taken by DAC phase. Positive TUNEL was stained as green and 
chromosomes were stained as blue. All Polar body showed a positive TUNEL (Green).
Table 11. Triplicate 16h ex vivo Oocyte Development Evaluation in the Presence o f  Vemurafenib Solutions
Groups Replicate Mean Number o f Oocytes ±SD (Mean Percentage iS D )
Number GV GVBD, MI M il Frag/D eg
Positive Control* 3 3 i  1 (18 ±4)*** 4 ±  1 (28 ± 4)*** 4 i  1 (24 i  3) *** 4 i  1 (28 i  4)***
Negative Control1* 3 0 i  1 (2 ± 4) 0 i  0 (0 i  0) 14 i  1 (95 i  4) 0 i  1 (2 i  4)
0.1 % DMSOc 3 0 ± 1 (2 ± 4) 0 i  1 (2 ± 4 ) 14 i  1 (96 i  8) 0 i  0 (0 i  0)
100 pMd 3 3 i l  (20 ±7)*** 6 i  1 (40 ±  7)*** 4 i 2  ( 2 9 i  10) *** 2 i  1 (11 i  3)
10 pMd 3 1 i  1 (9 ± 3) 3 ±  1 (17 ± 8)* 11 i  2 (71 i  10) 0 i  1 (2 i  4)
1 pMd 3 1 ± 1 (5 ± 4) 1 ±  1 (5 ±  4) 14 i  1 (91 i  3) 0 i  0 (0 i  0)
0.1 pMd 3 0 ± 1  (2 ± 4 ) 1 i  1 (5 ±  4) 13 i  2 (93 i  7) 0 i  0 (0 i  0)
0.01 pMd 3 1 i  1 (5 ±  4) O i l  (2 i 4) 14 i  1 (93 i  7) 0 i  0 (0 i  0)
*** Highly significantly difference from negative control, p <  0.001
a. Positive Control: composed o f 0.0000025% Zephiran Chloride with modified Kreb’s Bicarbonate Buffer (mKBB), which
has proven gemmate/embryo toxicity.
b. Negative Control: mKBB without DMSO.
c. 0.1% DMSO: DMSO dissolved in mKBB at a final concentration of 0.1% as DMSO control.
d. Serial dilution: Serially diluted from 100X stock solution made by Vemurafenib dissolved in DMSO and subsequently in 
mKBB to reach the concentration of 100 pM Vemurafenib 0.1% DMSO mKBB. And each concentration was adjusted to 
maintain the final DMSO concentration to 0.1%
Table 12. Triplicate Analysis of DNA Integrity in O ocytes 16h Post-Yemurafenib Treatment
Groups Replicate Mean Number of Oocytes ±SD (Mean Percentage ±SD)
Number TUNEL Positive TUNEL Negative
Positive Control* 3 15 ± 1 (98 ± 4 ) * * * 0 ±  1 (2 ± 4 ) * * *
Negative Control1’ 3 1 ±  1 (8 ±  4) 14 ±  1 (95 ±  4)
0.1 % DMSOc 3 1 ±  1 (9 ±  3) 14 ±  1 (91 ± 3 )
100 pMd 3 13 ± 2  (86 ± 7 ) * * * 2 ±  1 (14 ± 7)***
10 pMd 3 8 ± 0 (53 ±  0 )*** 1 ±  0 (47 ±  0 )***
1 pMd 3 3 ±  1 (18 ±  4) 12 ±  1 (82 ±  4)
0.1 pMd 3 1 ± 1 (7 ± 7) 13 ± 2  (93 ± 7 )
0.01 pMd 3 1 ±  1 (9 ±  8) 14 ±  1 (91 ±  8)
*** Highly significantly difference from negative control, p < 0.001
a. Positive Control: composed o f0.0000025% Zephiran Chloride with modified Kreb’s Bicarbonate Buffer (mKBB), which
has proven gemmate/embryo toxicity.
b. Negative Control: mKBB without DMSO.
c. 0.1% DMSO: DMSO dissolved in mKBB at a final concentration of 0.1% as DMSO control.
d. Serial dilution: Serially diluted from 100X stock solution made by Vemurafenib dissolved in DMSO and subsequently in 
mKBB to reach the concentration of 100 pM Vemurafenib 0.1% DMSO mKBB. And each concentration was adjusted to 
maintain the final DMSO concentration to 0.1%
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(86% ± 7%) o f  the oocytes (Table 12). However, the concentration 1 pM or below, 
which is below the therapeutic concentration, showed no significant difference from the 
control groups (p = 0.103). Almost all M il-arrested oocytes demonstrated a negative 
response to the DNA damage effect o f Vemurafenib.
However, after culturing with 10 pM  Vemurafenib 16h, oocytes which 
morphologically normal M il oocytes [11 ± 2 (71% ± 10%)] revealed a significant 
difference in DNA integrity compared with the control groups. Oocytes showed 8 ± 0 
(53% ± 0%) to be TUNEL positive (p 0.001). After correction, the morphologically 
normal M il-arrested oocytes with disintegration o f  DNA contributed another 24% weight 
to the actual incompetency o f  M il-arrested oocytes after 16h 10 pM Vemurafenib culture. 
In addition to GV-intact, MI and Frag./Deg. oocytes, 10 pM Vemurafenib revealed a 
significant statistical difference (p = 0.002) were found in 10 pM in which 8 ± 0 (53% ± 
0%) o f oocytes were incapable o f  further developmental events. Similarly, 100 pM 
Vemurafenib showed a highly significant difference from the control groups (p <
0.0001), with 86% ± 7% o f the oocytes incapable o f  further development. An 
approximate 15% decrease in ability to survive was observed in morphologically normal 
M il-arrested oocytes in the 100 pM Vemurafenib group (Table 12). The positive TUNEL 
assay showed massive DNA damage, which would prevent further development o f  the 
oocytes regardless o f the morphological appearance. Finally, all other lx  or lower 
concentration groups showed no difference from the 0.1% DMSO and negative control 
groups. TC'so is considered as 10 pM, whereas NC is 1 pM.
3.2 Ex Vivo 1C Mouse Embryo Development Quality Control Assay
3.2.1 Evaluation of 1C Embryo Development
The 1C embryos with two prominent pronuclei and narrow perivitelline space were 
collected from sexually mature B6CBA F|/J female mice. The 3 -week-old females were 
subjected to sequential 5 IU PMSG and 5 IU hCG injection 48h apart, followed 
immediately by mating with CD1 males. Embryos in fallopian tubes from plug-positive 
females 16h post-mating were isolated and cultured in pre-tested mKBB culture medium
67
with the serial dilutions o f anti-melanoma B-RafV600E drug Vemurafenib. Embryos in 
each developmental stage were evaluated by scoring. Different developmental stages 
were scored range from -1 to 5 points after exposure to different Vemurafenib 
concentrations after 38, 62, 86, 1 lOh culture: -1 point for degenerate or fragmented stage 
embryos; 0 point for 2C stage embryos; 1 point for 3-4C stage embryos; 2 points for 5-8C 
stage embryos; 3 points for morula stage embryos; 4 points for blastocyst stage embryos; 
5 points for hatching stage embryos and 3.5 points for collapsed embryos.
Treated (Vemurafenib serial dilutions) groups and control (positive, negative, 0.1% 
DMSO) groups were ranked by calculating and statistically analyzing the mean rank o f 
embryo development staging scores o f  groups in non-parametric one-way analysis o f 
variance test (ANOVA Kruskal-W allis test). To evaluate the embryonic toxicity and 
teratogenicity threshold o f  the Vemurafenib serial dilutions, the mean ranks o f treated 
groups for each concentration were compared with each other as well as with control 
groups. The higher the developmental score, the better the embryo developed.
A post-hoc comparison test (Mann-Whitney test) was run for testing the statistical 
ranking differences between paired comparisons groups o f each concentration and with 
control groups. To reduce the type I error o f  small degree o f freedom o f  compared 
groups and increase the accuracy o f the test, a Bonfeeroni adjustment (0.05/ [n (n -1 )/2]) 
for small degree o f freedom was used to increase the continuity o f the test results, where 
n is equal to the number o f the groups. The Observed Curve o f  the mean rank scores was 
plotted to explain the developmental behavior o f  1C embryos in the serial dilutions o f 
Vemurafenib exposure. The Observed Curve was closely represented by the Best-fit 
Curve, which is the theoretical curve. The closer the regression coefficient (R2) to 1, the 
more accurate the Best-fit Curve represents the Observed Curve. The regression formula 
and the R2 value were presented in 36, 62, 86 and 1 lOh graphs.
All preimplantation embryos in each concentration and control groups were 
regrouped into four developmental categories to magnify and pinpoint the toxicity effects 
o f the Vemurafenib in 62, 86 and 1 lOh post-culture. The categories were defined as: 
premorula (1-2C, 3-4C and 5-8C stages); morula-blastocyst (morula, blastocyst and 
collapsed blastocyst stages); hatching and fragmented-degenerated. The one-way 
ANOVA test was applied for evaluating statistical differences. The negative control
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group was shown to contain the most embryos progressing from the 1C to the hatching 
stage. Only a few embryos were incompetent to develop and proceed to either 
fragmented or degenerated embryos. Therefore, all the negative control groups the 
highest scores and best morphological results among all groups.
A p value of^O .05 throughout the results, was considered as statistically significant 
(*p ^  0.05, **p ^  0.01, ***p ^  0.001).
3.2.2 The Ex Vivo 1C Embryo Development Evaluation in Presence of Vemurafenib
To detect Vemurafenib toxicity on the 1C embryos, a mean rank o f the embryo 
development scoring was evaluated by comparing negative control and 0.1 % DMSO 
control. The result o f Kruskal-W illis test showed a significant difference among groups. 
In the Mann-Whitney paired comparison, concentrations below 10 pM. which was 10X 
the therapeutic concentration or lower, did not appear to be significantly different 
compared with control groups at 38, 62, 86 and 1 lOh (Table 13). A concentration o f  100 
pM, which is 100X the therapeutic concentration, shows a significant difference from the 
control groups (Table 13), beginning at the initiation o f the drug exposure [Mean rank 
score 100 pM (33.73 ± 10.92) versus negative control (63.57 ± 14.07), 38h after culture, 
pairwise p < 0.0001]. Significant toxic effect was observed at 100 pM, where embryos 
failed to develop to the blastocyst hatching stage. Embryos in 100X concentration o f 
Vemurafenib showed massive fragmentation and degeneration at the early stage o f 
culture. Toxicity remained to the end o f the 1 lOh observation frame. The toxicity o f 
Vemurafenib in the concentration o f 100 pM was even greater than the positive control 
[mean rank score 100 pM (33.73 ± 10.92) versus positive control (30.30 ± 11.64)] when 
compared to 38h after culture. The positive control mean rank score was reduced by the 
massive embryo degenerations and fragmentations. Embryonic
Table 13. Triplicate ex vivo 1C Embryo Development Evaluation in the Presence of Veimu afenib
Groups Replicate Kruskal-WillisMean Rank ANOVA Test o f  Embryo scorings ±SD
Number 38 h 62 h 86 h llO h
Positive Control1 3 30 .30±  11.64*** 13.78± 5.94*** 13.80± 5.52 *** 15.50±  3.97***
Negative Controlb 3 63 .57±  14.07 74.03 ± 12.45 74.36±  12.94 69.36 ±  12.45
0.1 % DMSO0 3 57.69 ± 10.84 66 .17±  10.86 63.47 ± 8 .8 7 63.70 ± 6 .8 6
100pM d 3 33.73 ± 10.92*** 25 .74±  5.14*** 25.08 ± 1.51 *** 19.84 ±3.41***
10 pMd 3 48.45 ± 14.83 56 .00±  17.08 44.83±  26.13 49.64 ± 2 3 .2 6
1 pMd 3 59.46 ± 20 .92 58 .68±  20.36 63.33±  12.96 70 .70±  15.94
0.1 pMd 3 64.65 ± 17.45 60.68 ± 16.45 69.17±  16.45 65.61 ± 14.64
0.01 pMd 3 62.39±  11.12 62.34 ± 2 1 .0 4 66.33 ± 12.81 66 .06±  9.78
*** Highly significantly different from negative control, p < 0.001
a. Positive Control: composed o f 0.000002 5% Zephiran Chloride with modified Kreb ’s Bicarbonate Buffer (mKBB), which
has proven gemmate/embryo toxicity.
b. Negative Control: mKBB withoutDMSO.
c. 0.1% DMSO: DMSO dissolved in mKBB at a fmal concentration o f  0.1% as DMSO control.
d. Serial dilution: Serially diluted from 100X stock solution made by Vemurafenib dissolved in DM SO and subsequently in 
mKBB to reach the concentration o f  100 pM Vemurafenib 0.1% DMSO mKBB. And each concentration was adjusted to 






























y = -1.2178x2 + 15.719x + 12.849 
R1 = 0.9197
i -------------------1  t.................  i-------------------1------------------ 1 i i

















Positive 100nM lOgM IjiM  0.1 jiM O.OljiM 0.1% Negative
Control DMSO Control
_ ControlConcentration
Figure 12. The Plotted Observed and Best-Fit Curve of Mean Rank Scores of
Embryo Development in Presence of Vemurafenib at 38h and 62h of Culture
(A and B) Concentration-related response o f  embryo developmental Best-fit Curve at 38 
and 62h o f  culture in presence o f Vemurafenib. Dashed curves represent observed data. 
Solid triangles are the mean rank scores o f  embryo development in various
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Figure 13. The Plotted Observed and Best-Fit Curve of Mean Rank Scores of 
Embryo Development in Presence of Vemurafenib at 86h and llOh of Culture
(A and B) Concentration related response o f  embryo developmental Best-fit Curve at 86 
and 11 Oh o f culture in presence o f  Vemurafenib. The dash curves represent the observed 
data. The solid triangles are the mean rank scores o f  embryo development in various 
concentrations. The solid curve (Best-fit Curve) explains the observed curve. R2: 
Regression coefficient.
Table 14. Triplicate 38h ex vivo 1C Embryo Development Evaluation in the Presence o f Vemurafenib Solutions
Groups Replicate Mean Number o f  Embryos ±SD  (Mean Percentage ±SD)
Number Premorula Morula-Blastocyst Hatched Frag/Deg
Positive Control3 3 12 ± 2  (98 ± 4 ) 0 ± 0 (0 ± 0) 0 ±  0 (0 ± 0) 0 ±  1 (2 ±  4)
Negative Controlb 3 14 ± 2  (100 ± 0 ) 0 ±  0 (0 ± 0) 0 ±  0 (0 ± 0) 0 ±  0 (0 ±  0)
0.1% D M SO C 3 12 ± 2  (100 ± 0 ) 0 ± 0 (0 ± 0) 0 ±  0 (0 ± 0) 0 ±  0 (0 ± 0)
100pM d 3 14 ± 5 (98 ± 4) 0 ±  0 (0 ± 0) 0 ± 0 ( 0 ±  0) 0 ± 1 (2 ±  4)
10 pMd 3 13 ± 4  (100 ± 0 ) 0 ± 0  ( 0 ± 0 ) 0 ± 0 ( 0 ± 0 ) 0 ± 0 (0 ±  0)
1 pMd 3 12 ± 3  (100 ± 0 ) 0 ± 0 (0 ± 0) 0 ±  0 (0 ± 0) 0 ± 0 (0 ± 0)
0.1 pMd 3 11 ± 3 (97 ± 6) 0 ±  1 (3 ± 6) 0 ±  0 (0 ± 0) 0 ± 0 ( 0 ± 0 )
0.01 pMd 3 12 ± 2  (100 ± 0 ) 0 ± 0 (0 ± 0) 0 ±  0 (0 ± 0) 0 ± 0 (0 ± 0)
a. Positive Control: composed o f 0.0000025%  Zephiran Chloride with modified Kreb’s Bicarbonate Buffer (mKBB), which 
has proven gemmate/embryo toxicity.
b. Negative Control: mKBB without DMSO.
c. 0.1% DMSO: DMSO dissolved in mKBB at a final concentration o f  0.1 % as DMSO control.
d. Serial dilution: Serially diluted from 100X stock solution made by Vemurafenib dissolved in DM SO and subsequently in 
mKBB to reach the concentration o f  100 pM Vemurafenib 0.1% DMSO mKBB. And each concentration was adjusted to 
maintain the final DMSO concentration to 0.1 %
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developmental pattern was compared at 38, 62, 86 and 1 lOh culture in the presence o f 
Vemurafenib. Each mean rank score from each hour point o f culture at different 
concentrations was represented by the solid triangle.
The Observed Curve connected mean rank scores by a dashed line, whereas the 
Best-fit Curve was represented by a solid line. The Best-fit Curve explained the 
Observed Curve in 92% (R2) at 38h, 92% at 62h, 95% at 86h and 90% at 1 lOh. All 
curves showed an obvious sharp incline and a plateau from 100 pM to the negative 
control (Figures 12 and 13). The Best-fit curve further proved that the concentration in 
100 pM o f Vemurafenib prevented over half the embryos from developing to the 
blastocyst hatching stage. Therefore, the TC50 for the 1C embryo development assay set 
at 100 pM. The categorized data analyzed by one-way ANOVA showed a pattern similar 
to the mean rank Kruskal ANOVA analysis. But the one-way ANOVA categorized 
analysis focused primarily on the general trend o f embryo development. At 38h culture, 
no major difference was found among groups (Table 14). However, at 62h culture, not 
only 100 pM Vemurafenib showed a highly significant difference in embryo 
development, but also 10 pM in concentration o f Vemurafenib solution demonstrated a 
delay in embryo development (Table 15). However, most embryos in the categorized 
premorula stage in 10 pM were at 7C or 8C stage (data not shown) and soon regained the 
rate o f embryo development compared to control group (Table 15). Concentrations 
below 10 pM did not demonstrate a significant difference from control groups at 38, 62, 
86 and 1 lOh (Table 14, 15, 16 and 17). Therefore, embryotoxicity has been clearly 
observed at 100X o f the therapeutic concentration. At the same time, potential delayed 
toxicity was observed in 10X Vemurafenib. However, the drug showed no significant 
morphological toxicity in vitro preimplantation 1C embryos.
3.2.3 The Ex Vivo 1C Embryo p-Mek 1/2 In Situ Immunofluorescence Staining for 
Embryo C-Raf Activity in Presence of Vemurafenib after 14h Culture.
The Mek 1/2 is the direct and only substrate o f  C-Raf in the MAPK pathway. 
Phosphorylation o f Mek 1/2 directly mirrors the kinase function and activity o f  C-Raf,
Table 15. Triplicate 621i ex vivo 1C Embryo Development Evaluation in the Presence o f Vemurafenib Solutions
Groups Replicate Mean Number o f  Embryos ±SD  (Mean Percentage ±SD)
Number Premorula Morula-Blastocyst Hatched Frag/Deg
Positive Control3 3 7 ± 0 ( 5 6  ±9)*** 0 ± 0 ( 0 ±  0) *** 0 ± 0 ( 0 ± 0 ) 6 ± 2 (44 ± 9)***
Negative Control1* 3 0 ± 0 (0 ± 0) 1 4 ± 2 ( 1 0 0 ± 0) 0 ± 0  ( 0 ± 0 ) 0 ± 0 (0 ±  0)
0.1 % DMSOc 3 1 ± 1 (11 ± 2) 11 ± 1 (87 ±  6) 0 ± 0 ( 0 ± 0 ) 0 ± 1 (2 ±  4)
100 pMd 3 9 ± 4  (73 ±41)*** 1 ± 1 (4 ± 6) *** 0 ± 0  ( 0 ± 0 ) 4 ± 7  (23 ±35)***
10 pMd 3 5 ± 1 (39 ± 10)* 8 ± 3 (61 ± 10)* 0 ± 0 (0 ± 0) 0 ± 0 ( 0 ± 0 )
1 pMd 3 4 ± 6 (33 ± 51)* 8 ± 7 (67 ± 51)* 0 ± 0 (0 ± 0) 0 ± 0 (0 ± 0)
0.1 pMd 3 3 ± 3  (31 ± 34)* 8 ±  5 (69 ± 34)* 0 ± 0 (0 ± 0) 0 ± 0 (0 ± 0)
0.01 pMd 3 3 ± 4 (29 ± 39)* 9 ±  5 (68 ± 36)* 0 ± 0 (0 ± 0) 0 ±  1 (3 ± 5)
*** Highly significantly difference ffomnegative control,p < 0.0001 
* Significantly difference from negative control, p < 0.05
a. Positive Control: composed o f 0.0000025%  Zephiran Chloride with modified Kreb’s Bicarbonate Buffer (mKBB), which
has proven gemmate/embryo toxicity.
b. Negative Control: mKBB withoutDMSO.
c. 0.1% DMSO: DMSO dissolved in mKBB at a final concentration o f  0.1 % as DMSO control.
d. Serial dilution: Serially diluted from 100X stock solution made by Vemurafenib dissolved in DM SO and subsequently in 
mKBB to reach the concentration o f  100 pM Vemurafenib 0.1% DMSO mKBB. And each concentration was adjusted to 
maintain the final DMSO concentration to 0.1 %
Table 16. Triplicate 86h ex vivo 1C Embryo Development Evaluation ill tlie Presence o f Vemurafenib Solutions
Groups Replicate Mean Number o f  Embryos±SD (Mean Percentage ±SD)
Number Premorula Morula-Blastocyst Hatched Frag/Deg
Positive Control3 3 1 ± 2  ( 1 2 ± 2 1 ) 0 ±  0 (0 ± 0) *** 0 ± 0 ( 0 ± 0 ) 11 ± 4 (88 ± 21)***
Negative Control1* 3 0 ± 0 (0 ± 0) 12 ± 4 (82 ± 2 1 ) 2 ± 3 (18 ± 21) 0 ± 0 ( 0 ± 0 )
0.1 % DMSOc 3 0 ± 1 (3 ± 5) 10± 3 (80± 21) 1 ± 1 (9 ± 9) 1 ± 1  (7 ± 7 )
100pM d 3 1 ± 2  (1 0 ± 16) 5 ± 4  (37 ± 30)*** 0 ± 0  (0±0)*** 8 ± 9 (54 ± 44)***
10 pMd 3 1 ± 1  (12 ± 10) 9 ± 4  (65 ± 14)*** 0 ± 1 (2 ±  3)* 3 ± 1 (21 ±8)***
1 pMd 3 0 ± 1 (3 ± 5) 12 ± 3  (94 ± 5 ) 0 ± 1 (3 ± 6) 0 ± 0 ( 0 ± 0 )
0.1 pMd 3 0 ± 0  ( 0 ± 0 ) 10 ± 4  (84 ± 13) 1 ± 1 (12 ± 7 ) 0 ± 1 (3 ±  6)
0.01 pMd 3 1 ± 0 ( 0 ± 0 ) 12 ± 2  (95 ± 5 ) 0 ± 1 (3 ±  5) 0 ± 1 (2 ± 4)
*** Highly significantly difference ffomnegative control,p < 0.0001
* Significantly difference from negative control, p < 0.05
a. Positive Control: composed o f 0.0000025% Zephiran Chloride with modified Kreb’s Bicarbonate Buffer (mKBB), which 
has proven gemmate/embryo toxicity.
b. Negative Control: mKBB without DMSO.
c. 0.1%DMSO: DMSO dissolved in mKBB at a final concentration of0.1% as DMSO control.
d. Serial dilution: Serially diluted from 100X stock solution made by Vemurafenib dissolved in DMSO and subsequently in 
mKBB to reach the concentration o f  100 pM Vemurafenib 0.1% DMSO mKBB. And each concentration was adjusted to 
maintain the final DMSO concentration to 0.1%
Table l 7. Triplicate llO lievvn'o 1C Embiyo Development Evaluation in the Presence o f Vemurafenib Solutions
Groups Replicate Mean Number o f Embryos ±SD (Mean Percentage ±SD)
Number Premorula Morula-Blastocyst Hatched Frag/Deg
Positive Control2 3 0 ± 0 (0 ± 0) 0 ± 0 ( 0 ± 0 ) * * * 0 ± 0 ( 0 ± 0 ) * * * 13 ± 2  (100 ±0)***
Negative Controlb 3 0 ± 0 (0 ± 0) 3 ± 4  (22 ± 2 3 ) 11 ± 2 (78 ± 23) 0 ± 0 (0 ± 0)
0.1 %DMSOc 3 0 ± 0 (0 ± 0) 4 ± 4 (27 ± 23) 8 ± 3 (69 ± 3 1 ) 1 ± 1 (7 ±  7)
100pMd 3 0 ± 1 (2 ± 4) 2 ± 1 (13 ± 7) 0 ±  1 (2 ± 4 )* * * 12 ± 5  (82 ± 12)***
10 gMd 3 0 ± 0 (0 ± 0) 5 ± 1 (37 ± 12)* 5 ± 4 (37 ± 17)*** 3 ± 1 (26 ±7)**
1 pMd 3 0 ± 0 (0 ± 0) 3 ± 4 ( 1 8 ±  25) 10± 1 (81 ± 2 0 ) 0 ± 1 (3 ± 5)
0.1 jiMd 3 0 ± 0 (0 ± 0) 4 ±  4 (28 ± 23) 8 ± 1 (69 ± 22) 0 ± 1 (3 ± 6)
0.01 pMd 3 0 ± 0 (0 ± 0) 4 ± 4 ( 2 7 ±  23) 8 ± 2 ( 7 1  ± 2 7 ) 0 ± 1 (2 ± 4)
*** Highly significantly difference from negative control, p < 0.0001
** Significantly different from negative control, p < 0.01
* Significantly different from negative control, p < 0.05
a. Positive Control: composed o f0.0000025% Zephiran Chloride with modified Kreb’s Bicarbonate Buffer (mKBB), which 
has proven gemmate/embryo toxicity.
b. Negative Control: mKBB withoutDMSO.
c. 0.1% DMSO: DMSO dissolved in mKBB at a final concentration o f 0.1% as DMSO control.
d. Serial dilution: Serially diluted from 1OOX stock solution made by Vemurafenib dissolved in DMSO and subsequently in 
mKBB to reach the concentration o f 100 pM Vemurafenib 0.1 % DMSO mKBB. And each concentration was adjusted to 
maintain the final DMSO concentration to 0.1%
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the potential target o f  Vemurafenib. C -Raf activity is responsible for the transition o f  1C 
to 2C and one o f  six lethal knockouts in post-implantation development. Therefore, the 
present study tested whether p-Mek 1/2 in morphological normal and abnormal embryos 
after 14h o f  culture mirrors the function o f C-Raf kinase.
A biotin-streptavidin signal amplification system was used to test the small amount 
o f  endogenous p-M ek 1/2. The biotin conjugated secondary antibody was used to bind 
the anti-p-Mek 1/2 (Ser217/221) antibody, followed by the Alexa-flour 488 fluorescent 
dye conjugated streptavidin activation for signal amplification. The blue DAPI stained 
chromosomes provided the reference point for p-Mek 1/2 cellular location.
Immunofluorescent images o f p-M ek 1/2 assay results after 14 hour culture o f 
Vemurafenib were photographed and evaluated under a Zeiss A1 inverted fluorescent 
microscope.
All 1C and Fragmented/ Degenerated embryos after 14h culture in Vemurafenib 
serial dilution solutions showed negative response in the Mek 1/2 phosphorylation by C- 
Raf. 2C embryos after 14h Vemurafenib culture showed either positive or negative p- 
Mek 1/2 fluorescence depending on Vemurafenib concentrations (Figure 14). Abnormal 
2C appearance often demonstrated negative or diminished p-Mek 1/2 fluorescence. Most 
o f  embryos in the 0.1% DMSO control, negative control groups, and 1 pM, 0.1 pM, and 
0.01 pM o f Vemurafenib formed 2C embryos with positive phosphorylation o f Mek 1/2 
(Table 18). Morphologically, embryos in 100 pM Vemurafenib showed that 7 ± 3 (49% 
± 6%) were unable to progress to 2C and within 2C stage cells; 4 ± 1 o f  the 2C embryos 
appeared to have either unequal blastomeres or prominent perivitelline spaces. A highly 
significant difference in morphological development (p < 0.001) was observed between 
the control groups and a concentration o f  100 pM Vemurafenib. However, a 
concentration o f 10 pM or lower, which is 10 times the therapeutic concentration or 
lower, showed no significant statistical and morphological difference from the control 
groups.
Similar to spindle-formation chromosome-alignment and DNA-integrity results, 
some morphological normal 2C embryos in concentrations o f 10 pM and 1 pM showed a 
negative result o f  p-M ek phosphorylation by C-Raf.
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Figure 14. Embryo Responses of C-Raf Activity after 16h Vemurafenib Exposure
(A. B and C) Pictures from one cell show A, normal 2C; B, p-Mek 1/2 IF staining 
positive (Green stained cytoplasmic substances); C, DAPI stained nucleus location 
(D. E and F) Pictures from one cell show D, abnormal 2C; E, p-Mek 1/2 IF staining 
negative(Green stained cytoplasmic substances); F, DAPI stained nucleus location. 
Concentration related response o f  embryo C -Raf activity (1C and 2C) by after 16h in 
presence o f Vemurafenib. Figures showed the p-Mek 1/2 IF staining o f  different 
responses o f embryos under influence o f Vemurafenib. Arrow heads show the nucleus 
outlines which indicate cytoplasmic location o f the p-MEK 1/2.
Figure 14 (Continued). Embryo Responses of C-Raf Activity after 16h Vemurafenib 
Exposure
(G, H and I) Pictures from one cell show G, abnormal 1C; H, p-Mek 1/2 IF staining 
negative (Green stained cytoplasmic substances); C, DAPI stained nucleus location 
(J, K and L) Pictures from one cell show J, degenerated embryo; K, p-Mek 1/2 IF 
staining negative (no stain); L, DAPI stained nucleus location.
Concentration related response o f embryo C -Raf activity (1C and 2C) by after 16h in 
presence o f Vemurafenib. Figures showed the p-Mek 1/2 IF staining o f different 
responses o f embryos under influence o f  Vemurafenib. Arrow heads show the nucleus 
outlines which indicate cytoplasmic location o f the p-MEK 1/2.
Table 18. Triplicate ex vivo 1C Embryo Developm ent Evaluation in the Presence O f Vemurafenib after 16h Cultures
Groups Replicate Number Mean Number o f  Embryos±SD (Mean Percentage ±SD)
1C 2C Frag/Deg
Positive Control3 3 4 ± 2  ( 2 6 ± 3 ) * 7 ± 4  ( 4 8 ± 5) *** 3 ± 1  (24 ± 4)*
Negative Control1* 3 0 ± 1 (2 ±  3) 15 ± 4 (94 ± 5) 1 ±  1 (4 ± 4)
0.1 % DMSO0 3 0 ± 1 (2 ±  4) 15 ± 5  (95 ± 4 ) 0 ±  1 (2 ± 4)
100pM d 3 5 ± 2  ( 3 4 ± 3 ) * 8 ±  3 (51 ± 5) *** 2 ± 1  ( 1 5 ± 3)*
10 pMd 3 2 ±  1 (12 ± 9 ) 13 ± 5  (82 ± 9 ) 1 ± 0 (7 ± 2)
1 pMd 3 1 ± 1 (8 ± 3 ) 15 ± 4 (90 ± 1) 0 ±  1 (2 ± 3)
0.1 pMd 3 1 ± 1 (5 ±  4) 14 ± 3  (94 ± 6 ) 0 ±  1 (2 ±  3)
0.01 pMd 3 0 ± 0 (0 ±  0) 16 ± 4 (100 ± 0) 0 ±  0 (0 ±  0)
*** Highly significantly difference from negative control, p < 0.0001 
* Significantly different from negative control, p < 0.05
a. Positive Control: composed of0.0000025% ZephiranChloridewithmodifiedKreb’sBicarbonateBuffer(mKBB), which
has proven gemmate/embryo toxicity.
b. Negative Control: mKBB without DMSO.
c. 0.1% DMSO: DMSO dissolved in mKBB at a final concentration o f  0.1 %  as DMSO control.
d. Serial dilution: Serially diluted from 100X  stock solutionmade by Vemurafenib dissolved in DM SO and subsequently in 
mKBB to reach the concentration o f  100 pM Vemurafenib 0.1% DM SOmKBB. And each concentration was adjusted to 
maintain the final DMSO concentration to 0.1 %.
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Two from 1 pM and four from 10 pM morphologically normal embryos showed negative 
responses to the Mek 1/2 phosphorylation, which represents 2% and 17% respectively o f 
actual incompetency o f the morphological normal 2C embryos. Combined results from 
the 1C embryo development assay in 3.2.2, indicate that while the negative p-Mek 1/2 2C 
embryos may develop through preimplantation stages, the embryos will not survive 
during post-implantation stages.
In 100 pM Vemurafenib, on the other hand, all abnormal appearance 2C (6 ± 2 (41% 
± 2%)) possessed a negative p-Mek 1/2 and morphologically normal 2C embryos (2 ± 1 
(10% ± 3%)) showed a positive p-Mek 1/2. This indicates that 100 pM had a higher 
embryotoxicity in the early stage o f  embryo development. This higher toxicity indicates 
that embryos progressing into 2C were incompetent to develop through the 
preimplantation stages.
Therefore, in addition to 1C and Frag./Deg. embryos. 100 pM and 10 pM 
Vemurafenib caused 13 ± 4 (83% ± 2%) and 5 ± 1 (35% ± 13%)respectively o f  C -Raf 
inhibition and showed a significant difference (100 pM, p < 0.001; 10 pM, p = 0.035) 
from the control groups (Table 19). However, a concentration o f 1 pM or lower, which is 
equal to or lower than therapeutic concentrations, showed no significant difference from 
the control groups after 16h o f culture.
Instead o f a complete block o f  C -Raf activity, most o f  the negative p-Mek 1/2 
showed diminished fluorescence. Since no other kinase exists for the phosphorylation o f 
Mek 1/2, the diminished fluorescence was completely due to the incomplete inhibition o f 
C-Raf activity. Even with this incomplete blockage, the reduction o f C -Raf activity is 
thought to be unable to support development o f embryos through pre- and post­
implantation stages (Yamauchi N et al., 1994; Yufen Xie et al., 2005).
Finally, regardless o f whether p-Mek 1/2 is inhibited, the presence o f  phosphorylated 
Mek 1/2 in the cytoplasm indirectly supports the conclusion that C -Raf located on the cell 
membrane activates the downstream effector Mek 1/2. Thus, negative p-M ek 1/2 by C- 
R af inhibition prevents the further development o f  the embryos regardless o f the
Table 19. Triplicate ex vivo Embryo Phospho-Mek 1 2  Staining for C-Raf Activity in Presence of Vemurafenib 
Solutions after 16h Cultures
Groups Replicate Mean Number o f Oocytes ±SD (Mean Percentage ±SD)
Number Phospho-Mek Positive Phospho-Mek Negative
Positive Control3 3 1 ± 1 (5 ±5)*** 13 ± 6  (95 ±5)***
Negative Control*5 3 15 ± 4  (90 ± 2 ) 2 ± 1  (10± 2)
0.1 % DMSO0 3 15 ± 5  (93 ± 6 ) 1 ± 1  ( 7 ± 6 )
100pMd 3 3 ± 1 (19±5)*** 13 ± 4  (83 ±2)***
10 pMd 3 1 0 ± 5 ( 6 5 ±  13)* 5 ± 1 (35 ± 13)**
1 pMd 3 14 ± 4  (88 ± 3 ) 2 ± 1  (12 ± 3 )
0.1 pMd 3 14 ± 3  (91 ± 2 ) 1 ± 1  ( 9 ± 2 )
0.01 pMd 3 16 ± 5 (97 ± 5 ) 0 ± 1 (3 ± 5)
*** Highly significantly different from negative control, p < 0.001
** Significantly different from negative control, p < 0.01
♦Significantly different from negative control, p < 0.05
a. Positive Control: composed o f0.0000025% Zephiran Chloride with modified Kreb’ s Bicarbonate Buffer (mKBB), which 
has proven gemmate/embryo toxicity.
b. Negative Control: mKBB withoutDMSO.
c. 0.1% DMSO: DMSO dissolved in mKBB at a final concentration o f 0.1% as DMSO control.
d. Serial dilution: Serially diluted from 100X stock solution made by Vemurafenib dissolved in DMSO and subsequently in 
mKBB to reach the concentration o f 100 pM Vemurafenib 0.1% DMSO mKBB. And each concentration was adjusted to 
maintain the final DMSO concentration to 0.1 %.
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morphological appearance. TCsois considered as 10 pM. whereas NC is 1 pM.
3.3 In Vivo Mouse Embryo Development Quality Control Assay
3.3.1 The 2C Embryo Development Evaluation Standards and Statistics
Two cell embryos with two equal blastomeres and narrow perivitelline spaces were 
collected from sexually mature BeCBAFj/J female mice. The 3-week-old females were 
subjected to sequential 5 IU PMSG and 5 IU hCG injections 48h apart, followed by 
immediately mating with CD1 males. Seven doses i.p. o f Vemurafenib (10 mg/kg) were 
also pre-injected in vivo twice daily. The first injection was administered 12h after 
PMSG injection and the last dose was administered 36h after hCG injection. Embryos in 
fallopian tubes from plug positive females 42h post-hCG were isolated and cultured in 
pre-tested mKBB culture medium. Embryos in each developmental stage were evaluated 
by scores. Scores o f Embryos at different developmental stages ranging from -1 to 5 
points after 24, 48, 72 and 96h culture: -1 point for Degenerate or Fragmented embryos; 0 
point for 2C embryos; 1 point for 3-4C embryos; 2 points for 5-8C embryos; 3 points for 
morula embryos; 4 points for blastocyst stage embryos, 5 points for hatching stage 
embryos and 3.5 points for collapsed embryos.
The treated (Vemurafenib serial dilution) groups and the control (positive, negative, 
0.1%DMSO) groups were ranked by calculating and statistically analyzing the mean rank 
o f embryo development staging scores by ANOVA Kruskal-Wallis test. The higher the 
developmental score, the better the embryo development.
A Post-hoc Mann-Whitney test was performed for testing the statistical ranking 
differences between paired comparisons groups o f  each concentration and with control 
groups. A Bonfeeroni adjustment was used to reduce the type I error, the small degree o f 
freedom, and to increase the accuracy o f the test.
The trend o f the mean rank scores was plotted to explain the tendency o f  the 2C 
embryo developmental behavior after in vivo Vemurafenib i.p. injections compared with 
control groups in 24 ,48 , 72 and 96h culture.
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All preimplantation embryos in the Vemurafenib dam injection group and control 
groups were regrouped into four developmental categories to magnify and pinpoint the 
toxicity effects o f  the Vemurafenib in 24, 48, 72 and 96h culture. The categories were 
defined as the same as in Aim 2. One-way ANOVA was applied for testing statistical 
differences.
3.3.2 The In Vivo 2C Embryo Development Evaluation after the Vemurafenib Dam 
Injection Procedure
Results o f  Kruskal-W illis test showed a significant difference among groups in 24, 
48, 72 and 96h o f  culture. In a Mann-Whitney paired comparison, the DMSO control 
group showed a higher score than negative control and Vemurafenib groups in the early 
culture. Therefore, a stimulating effect on embryos was observed in the DMSO group 
[mean rank score DMSO control 40.69 ± 18.43 versus negative control 19.36 ± 12.07, 
pairwise p < 0.001). The experimental group in which Vemurafenib was dissolved by 
DMSO demonstrated a similar development rate compared with the negative control 
group [Mean rank score 10 mg/kg Vemurafenib 24.55 ± 10.43 versus negative control 
19.36 ± 12.07, pairwise p = 0.263]. Therefore, the Vemurafenib group had either offset 
the stimulating effect o f  the DMSO or showed a significant delay in embryo development 
in early culture. As the time approached 72 and 96h culture (Table 20). embryo 
development o f the control group approached that o f  the DMSO group [negative control
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Table 20. Triplicate in vivo Embryo Development Evaluation In the Presence Of Vemurafenib
Dose Replicate Kruskal-Willis Mean Rank ANOVA Test of Embryo scorings ±SD
Number 24 h 48 h 72 h 96h
Negative Control3 3 19.36± 12.07 23.85± 13.47 24.31 ± 14.51 28.00± 13.55
0.1 % DMSOb 3 40.69 ± 18.43 *** 33.09± 14.68* 29.74± 14.80 32.06± 14.49
10 mg/kg Vem. 3 24.55± 10.43 23.71 ± 12.60 24.67± 12.26 19.31± 12.23 **
*** Highly significantly different from negative control, p < 0.001 
** Significantly different from negative control, p < 0.01 
* Different from negative control, p <0.05
a. Negative Control: mKBB only without DMSO.
b. 0.1% DMSO: DMSO dissolved in mKBB as final concentration of 0.1% as DMSO control.
24.31 ± 14.51 (72h) and 28.00 ± 13.55 (96h) versus DMSO control 29.74 ± 14.80 (72h) 
and 32.06 ± 14.49 (96h)], whereas the Vemurafenib group showed a gradual decline o f 
development rate and. a significant delay in embryo development [mean rank score=
19.31 ± 12.23 (96h), p = 0.007]. Vemurafenib also clearly prevented hatching o f  the 
blastocyst in expanded blastocyst embryos.
Similar to the mean rank score comparisons, the plotted trend o f mean rank scores 
(Figure 15) showed that the embryo development o f  the 10 mg/kg Vemurafenib injection 
group, compared with the DMSO and negative control groups, had either offset the 
stimulating effect o f the DMSO or showed a significant decline in embryo development 
at the early time o f  culture (24, 48 and 72h). However, 10 mg/kg Vemurafenib injections 
possibly delay the process and significantly compromise the blastocyst hatching process. 
9 ± 3 (53% ± 14%) embryos failed to hatch out o f  the zona pellucida at 96h post-culture.
Categorized data analyzed by the one-way ANOVA test showed a pattern similar to 
the mean rank Kruskal-W illis ANOVA analysis. Although no significant differences 
between experimental and control groups were observed at 48 and 72h, at 24h o f culture 
the one-way ANOVA test revealed that the DMSO group approached the more
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Figure 15. The Plotted Kruskal-Willis Mean Rank Scores Trend
The plotted Kruskal-W illis mean rank scores trend o f embryo development after 
Vemurafenib dam injections at 24, 48, 72 and 96h o f  culture. The Vemurafenib dam 
injection group showed a delayed effect on embryo development in the embryo 
preimplantation stages. Dotted lines and squares represent the mean rank scores and 
score trend o f  DMSO control group. The solid line and squares are the mean rank scores 
and score trend o f  the Vemurafenib dam injection group. The dashed line and diamonds 
are the mean rank scores and score trend o f the negative control group.
Table 21. Triplicate in vivo 24 h Embryo Development Evaluation in the Presence of Vemurafenib Solutions
Groups Replicate
Number
Mean Number of Embryos ±SD (Mean Percentage ±SD)
Premorula Morula-Blastocyst Hatched Frag/Deg
Negative Control3 3 21 ± 10 (96 ±3) 1±1 (4±3) 0 ± 0 (0 ± 0) 0 ± 0 (0 ± 0)
0.1 % DMSOb 3 5 ±7  (26±32)*** 6±2 (74± 32)*** 0 ± 0 (0 ± 0) 0 ± 0 (0 ± 0)
10 mg/kg Vem. 3 16 ± 9 (86 ± 10) 2 ± 1 (11 ± 7) 0 ± 0 (0 ± 0) 0 ± 0 (0 ± 0)
*** Highly significantly different from negative control, p < 0.001
a. Negative Control: mKBB only without DMSO.
b. 0.1%DMSO: DMSO dissolved in mKBB as final concentration of 0.1% as DMSO control.
Table 22. Triplicate in vivo 48 h Embryo Development Evaluation in the Presence of Vemurafenib Solutions
Groups Replicate Mean Number of Embryos ±SD (Mean Percentage ±SD)
Number Premorula Morula-Blastocyst Hatched Frag/Deg
Negative Control3 3 0 ± 1 (3 ± 4) 20 ± 12 (87 ± 16) 0 ± 0 ( 0 ± 0 ) 0 ± 0 ( 0 ± 0 )
0.1 % DMSOb 3 0 ± 0 ( 0 ± 0 ) 11 ± 9 (100 ± 0) 0 ± 0 ( 0 ± 0 ) 0 ± 0 ( 0 ± 0 )
10 mg/kg Vem. 3 1 ± 1 (2 ± 4) 17 ± 7 (95 ± 4) 0 ± 0 (0 ± 0) 0 ± 0 ( 0 ± 0 )
a. Negative Control: mKBB only without DMSO.
b. 0.1%DMSO: DMSO dissolved in mKBB as final concentration of 0.1% as DMSO control.
Table 23. Triplicate in vivo "2h Embryo Development Evaluation in the Presence of Vemurafenib Solutions
Groups Replicate Mean Number o f Embryos ±SD (Mean Percentage ±SD)
Number Premorula Morula-Blastocyst Hatched Frag/Deg
Negative Control3 3 0 ± 0 ( 0 ± 0 ) 1 8 ± 7 ( 8 3 ±  14) 4 ± 4 (16± 14) 0 ±  1 ( 1 ± 2 )
0.1 % DMSOb 3 0 ± 0 (0 ± 0) 7 ± 6 (62 ± 22)** 4 ± 4 (38 ± 22)** 0 ± 0 ( 0 ± 0 )
10 mg/kg Vem. 3 0 ± 0 ( 0 ± 0 ) 14 ± 8 (80±  9) 3 ± 2  (18± 12) 0 ± 0 (0 ± 0)
** Highly significantly different from negative control, p < 0.001
a. Negative Control: mKBB only without DMSO.
b. 0.1%DMSO: DMSO dissolved in mKBB as final concentration o f 0.1% as DMSO control.
Table 24. Triplicate in vivo 96 h Embryo Development Evaluation in the Presence of Vemurafenib Solutions
Groups Replicate Mean Number o f Embryos ±SD (Mean Percentage ±SD)
Number Premorula Morula-Blastocyst Hatched Frag/Deg
Negative Control3 3 0 ± 0 (0 ± 0) 3 ± 2 (16 ± 6) 18 ± 9  (83 ± 6 ) 0 ± 1 (1 ± 2)
0.1 % DMSOb 3 0 ± 0 (0 ± 0) 0 dh 0 (0 ± 0) 10 ± 8  (98 ± 3 ) 0 ± 1 (2 ±  3)
10 mg/kg Vem. 3 0 ± 0 (0 ± 0) 9 ± 3  (53 ± 14)*** 8 ± 6 (44 ± 13)*** 2 ± 3  (1 7 ± 2 6 )
*** Highly significantly different from negative control, p <  0.001
a. Negative Control: mKBB only without DMSO.
b. 0.1% DMSO: DMSO dissolved in mKBB as final concentration of0.1% as DMSO control.
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advanced stages faster than the Vemurafenib and negative control groups (p = 0.0006) 
stages. At 96h, the group with a 10 mg/kg dose o f  Vemurafenib injection showed a 
significant incompetency in blastocyst hatching and delayed progression to an expanded 
blastocyst, (p = 0.003).
Therefore, Vemurafenib injections did not show an acute toxicity. The long half- 
life o f  Vemurafenib, cultured only in media after embryo collection, showed a mild and 
delayed toxic influence throughout embryo development. However, the drug did not 




One o f the important concerns o f the safety o f  the anticancer drug therapy is 
whether the drug supports the normal development o f  the embryo and fetus.
Vemurafenib is approved by the FDA as a MM target therapy because o f its rapid 
response and the overall increase o f survival rate and free progression period compared 
with the classical chemotherapeutical agent dacarbazine in malignant melanoma (MM) 
(Chapman et al., 2011). However, lack o f research data and clinical references to 
Vemurafenib safety has greatly limited the medical treatment options for pregnant, 
lactating and potentially pregnant MM patients who are urgently seeking effective 
medications. Therefore, evaluation o f the embryo and oocyte toxicity o f  the anti­
melanoma B-RafV600E inhibitor Vemurafenib is essential to provide an understanding o f 
its benefit to newly pregnant, lactating and potentially pregnant women with MM. We 
hypothesized that Vemurafenib has detrimental effects on oocyte maturation and/or the 
embryo development. Results from the tested hypothesis, explanation o f the results, and 
its putative underlying mechanism will be discussed in this chapter.
4.1 Impacts on Ex Vivo Oocyte Maturation, Spindle-Chromosome Behavior and 
DNA Integrity
The tested hypothesis was that Vemurafenib produced detrimental effects on ex vivo 
mouse oocyte maturation from the GV-intact oocyte to the M il arrest, as well as spindle 
apparatus formation, chromosomal alignment, and DNA integrity.
After 16h o f culture, the majority o f oocytes from 10 pM to the 0.1 % DMSO 
control successfully progressed to the MH-arrest stage. All oocytes in the negative 
control group progressed to the M ll-arrest stage. Only a few oocytes in these groups 
were confined to GV-intact, MI and Fragmented/Degenerated stages. Most o f  the 
oocytes in the 100 pM group were arrested at the MI stage [5 ± 2 (36% ± 10%) versus 0
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± 1 (2% ± 4%) at MI stage]. The difference between the MI and Control groups showed 
that the majority o f oocytes were incompetent to mature into MH-arrest stage and that 
fragmentation and degeneration could also be seen in this group. The 100 pM group 
displayed a pattern similar to the positive control group, which produced a clear oocyte 
toxic effect. A significant oocyte toxic effect had been observed at 100 pM. One hundred 
pM Vemurafenib caused 8 ± 3 (54% ± 16%) spindle formation abnormalities, and the 
majority (72% ± 13%) o f chromosome misalignments (Table 8). At concentrations o f  1 
pM or lower, almost all oocytes progressed to the MH-arrest stage with barrel shaped 
spindle fibers and correctly aligned chromosomes.
Morphologically normal 10 pM Vemurafenib oocytes showed 8 ± 0 (53% ± 0%) 
chromosome misalignment (P=0.0009) after 16h Vemurafenib exposure. An additional 
31 % ± 6% increase in incompetency o f the M ll-arrest oocyte number —added to the pool 
o f GV-intact, MI and Fragmented/ Degenerated oocytes at the 10 pM level—revealed the 
underlined oocyte toxicity on the spindle formation and chromosome alignment, in which 
24% ± 11% o f oocytes were incapable for further developmental events. We observe 
that the higher the concentration, the greater the number o f oocytes confined at MI stages.
Similarly, 100 pM Vemurafenib produced 82% ± 4% o f DNA fragmentations. In 1 
pM Vemurafenib or lower, almost all M ll-arrest oocytes demonstrated a negative 
response to the DNA damage effect o f Vemurafenib. However, morphologically-normal 
M ll-arrest oocytes with disintegration o f DNA in 10 pM Vemurafenib contributed to an 
additional 33% weight to the actual incompetency o f M ll-arrest oocytes, with 10 pM 
showing clear toxicity to the oocyte DNA.
The Ras/C-Raf MAPK pathway acts as an important self-enhancing and self- 
promoting system. The pathway is involved in MPF synthesis and activation, which in 
turn affects GVBD and M il progression. The MAPK pathway also actively participates 
in spindle apparatus formation and chromosome alignment. Specifically, the MAPK 
pathway has been shown to be involved in Microtubule Organizing Center (MTOC) 
formation in mouse oocyte maturation (Verlhac et al., 1994). The spatial co-localization 
o f  MAPK with the metaphase spindle during meiosis I to II transition indicates a close 
relationship between them in the mouse oocyte (Hatch et al., 2001; Lee et al., 2000). 
Several studies o f the mouse oocyte have found that the genetic knockouts along the
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MAPK pathway (like Mos, Erk2) showed a failure to achieve the normal spindle 
assembly (Araki et al., 1996; Bodart et al., 2002; Choi et al., 1996; Zhao et al., 1991). 
Moreover, recent research shows that 75% MAPK activity causes a disturbed spindle 
with dispersed chromosomes, whereas 45% MAPK activity leads to a disintegrated 
spindle with scattered chromosomes. A disturbed spindle apparatus and unaligned 
chromosomes triggers apoptotic events and results in fragmentation o f the DNA 
molecule. Not only are 10 pM and 100 pM Vemurafenib a B-Raf inhibitor, but also C- 
Raf, which is the main component o f  the MAPK pathway, is inhibited. Therefore. 1 Ox 
and lOOx Vemurafenib concentrations were shown to lead to spindle disturbance, 
chromosome misalignment, and DNA damage.
4.2 Impacts on Ex Vivo 1C Embryo Development and Quality
The tested hypothesis was that Vemurafenib produced detrimental effects on ex vivo 
1C mouse embryo development and Mek 1/2 phosphorylation through C -R af activity.
The concentrations below 10 pM, which was 1 OX the therapeutic concentration or 
lower, did not appear to be significantly different compared with control groups at 38, 62. 
86 and 1 lOh (Table 13).
A significant toxic effect on embryo development was observed at the 100 pM level, 
with no embryos reaching the blastocyst hatching stage. Toxicity was observed at the 
very beginning o f  drug exposure (Mean rank score 100 pM (33.73 ± 10.92) versus a 
negative control rate (63.57 ± 14.07), 38h after culture, pairwise p < 0.0001). Embryos 
showed massive fragmentation and degeneration (mean rank score 100 pM (33.73 ±
10.92) compared with the positive control (30.30 ± 11.64)) at 38h after culture. Toxicity 
remained to the end o f  11 Oh observation frame.
The categorized data analyzed he general trend by the one-way ANOVA test, 
showed a pattern similar to the mean rank Kruskal ANOVA analysis. At 62h o f culture, 
not only did 100 pM Vemurafenib show high toxicity in embryo development, but also 
10 pM Vemurafenib demonstrated a delay in embryo development, during which most o f 
the embryos were at 7C or 8C stage (Table 14). However, the 10 pM group recovered 
the rate o f embryo development as the time elapsed.
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In the 1C p-Mek 1/2 IF assay, developmental morphology o f 1C to 2C was again 
evaluated. Similarly, embryos in 100 pM Vemurafenib showed 7 ± 3 (49% ± 6 %) were 
unable to progress to 2C, and within 2C stage cells. 4 ± 1 2C embryos appeared to have 
either unequal blastomeres or a prominent perivitelline space. The 10 pM or lower 
Vemurafenib showed no obvious morphological toxicity compared with control groups. 
However. 2 and 4, respectively, from 1 pM and 10 pM morphologically normal embryos 
showed negative responses to the Mek 1/2 phosphorylation by C-Raf, giving a difference 
o f 2% and 17%, respectively, o f abnormal morphology when compared to the normal 2C 
embryos. In addition to 1C and Frag/ Deg embryos, 100 pM and 10 pM showed a 
phosphorylation inhibition o f p-Mek 1/2, decrease o f C -Raf activity, and clear toxicity to 
the 1C to 2C transition o f  embryos.
All abnormal 2C showed negative p-Mek 1/2 and were incompetent to develop 
through the preimplantation stages. More than 80% o f named “negative" p-M ek 1/2 
showed diminished fluorescence, which was an incomplete block o f the C -Raf activity 
but proved to be unable to support embryo development.
The Ras/C-Raf/Mek MAPK pathway functions as the downstream effectors o f the 
FGF receptor and other Receptor Tyrosine Kinase (RTK) receptors. Ras inhibitions 
halted the mouse embryo in the early 2C stage and could be completely recovered by 
constitutive transduction o f  the C-Raf molecule. C-Raf is the downstream effector o f Ras 
in the embryo development (Yamauchi et al., 1994). Later experiments showed that 
phosphorylated C-Raf activation was found in the M-phase-specific cell cycle in early 
cleavage stage o f 2C embryos (Haraguchi et al., 1998). Membrane localization in active 
pC-Raf in embryonic day 2.5 indicates that C -Raf activates the MAPK pathway from the 
cell membrane instead from the nucleus as usual (Wang et al., 2004). Further, 
phosphorylation o f Mek, the only downstream effector o f C-Raf, was shown to be 
expressed in the preimplantation embryo (Liu et al., 2004). C-Raf was shown to be one 
o f six causes o f  lethal null post-implantation mutations, resulting in the post-implantation 
or placental lethality (Yufen Xie et al., 2005). Therefore, lOx and lOOx Vemurafenib 
concentrations inhibit C -Raf activity and led to abnormal 2C formation. However, 1 pM 
Vemurafenib appears to nontoxic to the ex vivo 1C embryo transition to 2C and p-Mek 
1/2 by complete C -Raf activity.
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The 10 pM Vemurafenib-exposed embryos in ex vivo culture progressed with no 
significant morphological toxicity to the blastocyst hatching stage; however, the p-Mek 
1/2 IF assay proved to be significantly different from the control group. This difference 
indicated that some 2C could still survive. Other pathways may bypass the MAPK 
pathway blocking effects o f the embryo.
4.3 Impacts on In Vivo 1C Embryo Development and Quality
The current study tested the hypothesis that Vemurafenib possessed detrimental 
effects on 2C mouse embryo development after multiple in vivo 10 mg/kg Vemurafenib 
dam ’s injections.
Results showed that a stimulating effect on embryos had been observed in the 
DMSO group (Mean rank score DMSO control (40.69 ± 18.43) versus negative control 
(19.36 ± 12.07), pairwise p < 0.001) at 24 and 48h o f  culture. However, the experimental 
group in which Vemurafenib was dissolved by DMSO lost this stimulating effect and 
showed a similar rate o f  development as the negative control group (Mean rank score 10 
mg/kg Vemurafenib (24.55 ± 10.43) versus negative control (19.36 ± 12.07), pairwise 
P=0.263). As the time progressed from 72 to 96h culture, embryo development o f the 
control group recovered the o f  the DMSO group [negative control 24.31 ± 14.51 (72h) 
and 28.00 ± 13.55 (96h) versus DMSO control 29.74 ± 14.80 (72h) and 32.06 ± 14.49 
(96h)]. The 10 mg/kg therapeutic dose o f  Vemurafenib showed a delay in embryo 
development in earlyh o f  culture, a gradual decline in the development rate, and 
significant delay in embryo development (mean rank score= 19.31 ± 12.23 (96h), 
P=0.007). Vemurafenib also caused 9 ± 3 (53% ± 14%) embryos to fail to hatch out o f 
the zona pellucida and eventually to collapse. The categorized data analyzed by one-way 
ANOVA showed a similar pattern o f the mean rank Kruskal-W illis ANOVA analysis.
4.4 Future Work
The question o f  whether normal looking 2C embryos o f the incomplete p-Mek 1/2 
blockage are capable o f  future developmental is yet not answered. Also, a detailed study 
o f  the mechanism o f a delayed effect (collapsed embryos) o f  in vivo Vemurafenib
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injections is required to assure the toxicity-free effect to the preimplantation embryo and 
oocyte. This current research did not provide all safety information for the post­
implantation stage o f  embryo and fetal development. Because all oocytes have already 
completely formed in fem ale's fetus stage, any permanent damage to the oocytes will 
remain in her reproductive age and cause potential incompetency o f  pregnancy. Research 
on toxicity o f Vemurafenib on oocyte competency by testing post-implantation embryo 
and fetus in multiple ending pregnancy test will show clear evidence o f  oocyte permanent 
damage by Vemurafenib exposure. Therefore, assessments and data for fetal and/or 
childhood organ and systemic differentiations, development, and function are required to 
address the safety o f the drug. The risk o f congenital malformations also needs to be 
ruled out if  embryogenesis occurred after exposure o f cytotoxic drugs. Further 
developmental evaluation, toxicity mechanisms and combinational therapies for the drug 
must be addressed. Finally, since some aneuploidy such as blastocysts with D ow n's 
Syndrome (trisomy 21), Patau Syndrome (13 trisomy), Edward Syndrome (18 trisomy). 
Klinefelter Syndrome (extra X in males), Turner Syndrome (lack o f one X in females)) 
have perfectly normal morphology, detailed mechanism researches about chromosome 
karyotype analysis should be performed to rule out the possibilities o f chromosome 
abnormality under the influence o f  Vemurafenib.
4.5 Dissertation Significance
Although 46 ongoing Vemurafenib clinical trials are being conducted and multiple 
studies on pharmacological mechanisms, efficiency, toxicities and resistance o f 
Vemurafenib have been completed, none related mouse oocyte maturation toxicity and 
embryo toxicity to Vemurafenib exposure. This lack o f  research data on the potential 
toxicity o f  Vemurafenib in MM patients has caused doctors to be hesitant to prescribe or 
even suggest this first-line drug to the pregnant, lactating and potentially-pregnant 
woman with MM. The current study evaluated Vemurafenib exposure on mouse oocyte 
maturation and embryo toxicity. Results will enhance our understanding o f  whether 
Vemurafenib is suitable for pregnant, lactating and potentially-pregnant patients with 
MM. Such information is a critical benefit for women facing the legal issues o f  abortion,
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the family expectation on having offspring, time urgency and, most importantly, drug 
safety on oocyte, embryo and fetal development and maturation. This study suggests 
many further directions o f Vemurafenib exposure upon (1) mouse embryo implantation 
in the uterus; (2 ) mouse embryo post-implantation and fetal toxicity and teratogenicity 
including, organ and systemic differentiations, development and functionalities; (3) 
cytogenic, histological and molecular biological mechanisms o f the above toxicity and 
teratogenicity; (4) future toxicological studies concerning larger animals; (5) future 
clinical trials o f  Vemurafenib effects on human oocyte maturation, embryo and fetal 
toxicity, and teratogenicity; (6 ) detailed cytogenic, histological and molecular biological 
mechanism study for postpartum infant evaluation; and (7) evaluation o f potential 




The current research hypothesized that Vemurafenib causes detrimental effects on 
oocyte maturation and/or embryo development.
Aim 1 sought to determine whether Vemurafenib produced detrimental effects on 
ex vivo mouse oocyte maturation from the GV-intact oocyte to M il arrest, as well as 
spindle apparatus formation, chromosomal alignment, and DNA integrity. Results 
showed that 10 pM and higher toxicities to the oocyte disturb spindle apparatus 
formation and cause chromosomal misalignment and DNA damage. The higher the 
concentration, the more the oocytes are confined at MI stages whereas 1 pM 
Vemurafenib, the therapeutic concentration, does not possess significant oocyte 
morphological toxicity in ex vivo oocytes. Concentrations o f lOx and lOOx Vemurafenib 
lead to spindle disturbance, chromosome misalignment and DNA damage. But the 
therapeutic concentration o f the Vemurafenib appears to be nontoxic to the ex vivo oocyte 
maturation, spindle formation, chromosome alignment and DNA integrity. TC?o is 
considered as 10 pM, whereas NC is 1 pM. This study did not study whether 
Vemurafenib at therapeutic concentrations promoted aneuploidy oocytes which will be 
relevant for future healthy embryo development.
Aim 2 sought to determine whether Vemurafenib possessed detrimental effects on 
ex vivo 1C mouse embryo development and Mek 1/2 phosphorylation through C-Raf 
activity. Results showed that 100 pM and 10 pM concentrations produced the 
phosphorylation inhibition o f  p-Mek 1/2, a decrease o f C-Raf activity, and clear toxicity 
to the 1C to 2C transition o f  embryos. All abnormal 2C showed negative p-M ek 1 /2 and 
were incompetent to develop through the preimplantation stages. However, Vemurafenib 
in 1 pM concentration is no significant morphological toxicity on ex vivo preimplantation 
1C embryo development; especially, on the ex vivo 1C to 2C embryo transition and p- 
Mek 1/2 by complete C -Raf activity was observed. TCso is considered as 10 pM, 
whereas NC is 1 pM.
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Aim 3 sought to determine whether Vemurafenib produced detrimental effects on 
2C mouse embryo development after in vivo multiple 10 mg/kg Vemurafenib dam 
injections. The results showed that the 10 mg/kg Vemurafenib dam injections did not 
produce an acute toxicity. The long half-life o f  Vemurafenib showed only a mild delayed 
toxic influence (delay effect) throughout embryo development. However, most o f the 
embryos could progress to at least normal blastocysts and did not show any in vivo 
massive degenerative embryotoxicity in preimplantation embryos.
Finally, this research concludes that Vemurafenib in a therapeutic concentration 
was free o f ex vivo oocyte and embryo morphological toxicity, but in vivo toxicity on 
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1. Mouse Oocyte Maturation Assay and Mouse 1C and 2C Embryo Development 
Quality Control Assay
Until the present time, mouse oocyte maturation and embryo development assays 
have been considered the most reliable bioassays for quality assurance/quality control 
(QA/QC) determination and validation o f gamete and embryo research (Tucker & Jansen. 
2004).
The mouse embryo assay, either zygote stage or 2C stage, is a recommended 
bioassay for evaluating culture medium prior to use in human clinical treatment (ASRM, 
1992; Dandekar et ah, 1984). In addition the oocyte cell progression from GV to GVBD 
to M-II also showed the value o f oocyte maturation evaluation over a long period (Bodart 
JFL el ah, 2005). Mouse oocyte and embryo models are used to evaluate aspects o f new 
protocols, physical materials, and culture media which cannot be assessed using physical 
equipment (Scott, et ah, 1993; Naz et ah, 1986).
Mouse oocyte and embryo models have significant financial, management and 
ethical advantages over human embryos in toxicity studies. Mouse oocyte maturation 
and embryo development assays have been used to screen compounds added to cultures 
for potential toxicities (Condon-Mahony et ah, 1986; Fleming et ah, 1987; McDowell et 
ah, 1988; Bastias et ah, 1993). Both assays have also been used for testing potential 
developmental toxic effects o f clinical drugs (anesthetic formulations), environmental 
pollutants (methyl tertiary butyl ether) as well as pressure-treated lumber additives (Cr0 3. 
CuO and AS2O5). Mouse gametes and embryo development assays remain valuable 
models for evaluating operational procedures, drugs, and potentially toxic agents before 
using these drugs in clinical situations.
Scoring systems in in vitro fertilization (IVF) have been used for many years for 
oocyte, zygote and embryo parameters evaluation. The most frequently applied method 
for evaluating gamete and embryo competencies is the morphology analysis. An analysis 
must possess the quality o f being easy to assess, causing minimal impact on gametes and
112
embryos, and maintaining result objectivity (Machtinger R et al., 2013). Further analysis 
such as chromosome integrity, metabolic activity, and genomic activation detection, 
while potentially beneficial, is not necessary for gamete and embryo evaluation (Munne S 
et al., 1999, Steuerwald N et al., 1999; Van Blerkom J el al., 1991; Conaghan J et al., 
1993; Gardner DK, 2001). Because the accuracy or precision o f oocyte competency 
prediction could not be achieved by any indirect assays, evaluation o f the morphology o f 
the oocytes is believed to be the most efficient marker o f oocyte maturation competency. 
Also, oocyte spindle formation and chromosome alignment in MI and M il nuclear 
maturation is the best indicator o f  cytoplasmic maturation.
2. Spindle Apparatus and Chromosome IF Staining
The correct separation o f homologous chromosomes during the telophase o f meiosis 
I and segregation o f  the sister chromatids during meiosis II play a critical role in avoiding 
aneuploidy (Hassold T, et al., 2001). Abnormal segregation o f the chromosomes or 
chromatins is often due to the meiotic non-disjunction and is normally incompatible with 
normal oocyte and embryo development. Many non-lethal chromosomal diseases are 
associated with incorrect non-disjunction segregation [e.g., Down Syndrome (21 
trisomy), Patau Syndrome (13 trisomy), Edward Syndrome (18 trisomy), Klinefelter 
Syndrome (extra X in males), Turner Syndrome (lack o f one X in females)] (Angell RR 
et al., 1994). Approximately one third o f all miscarriages and twenty percent o f  human 
embryos are aneuploidies and are the leading cause o f the genetic disorders, development 
disabilities and mental retardations (Wyrobek AJ et al., 2006).
Direct immunofluorescence staining has demonstrated its accuracy in capturing the 
spindle apparatus formation and chromosome alignment in much research over a long 
period o f time (Santanu De et al., 2013; Nervana TEM, 2003; Jashoman Banerjee et al., 
2012; Wei Cui et al., 2012; Wolfgang Staiber, 2012; G. Bradley Alsop 2003). In the 
present study, the microtubules and chromosomes o f  Vemurafenib-exposed oocytes in all 
developing stages were directly stained by fluorescence-dye-conjugated antibody after 
being fixed and permeated with Microtubule-stabling buffer (MTSB) and blocked by 
blocking solution. In this way, variously shaped spindle apparatus and chromosomal
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alignments were examined and evaluated under the Zeiss A l inverted fluorescent 
microscope.
3. DNA Integrity TUNEL Assay
Even with a perfect appearance at the microscopic level o f the formation o f  the barrel 
shaped spindle apparatus and chromosome alignment after IF staining, we could not rule 
out the possibility o f tiny damages to the DNA molecules by Vemurafenib exposure.
This technique is suitable for fixed samples from all stages o f  the oocyte culture. 
Apoptosis in any stage o f  the oocyte is landmark o f  programmed self-destruction.
Oocyte apoptosis is carefully executed by the activation o f the nucleases, which break 
down the nuclear DNA into approximately 200bp DNA in length. Large numbers o f  3 '- 
hydorxyl ends are exposed when DNA breaks after initiation o f the apoptosis. These 3 ’ 
hydroxyl endings are the major target for deoxynucleotidyl transferase (TdT), which adds 
deoxyribonucleotide in a template-independent manner. The 5-bromo-2'-deoxyuridine 
5 -triphosphate (Br-dUTP) can be added to the mixture o f reaction-led TdT to act as the 
labelling units o f deoxyribonucleotide extensions. The Br-dU can be detected by the 
anti-Br-dU antibody conjugated by fluorescent dye. This immunohistochemical 
technique, named Terminal Deoxynucleotide Transferase dUTP Nick End Labeling, or 
TUNEL, accurately and unambiguously detects DNA fragments and is considered one 
reliable method for apoptotic cells identification. In our case, the Br-dU was detected by 
Alexa Fluor® 488 dye-labeled anti-Br-dU antibody, which has an excitation and 
emission spectrum similar to FITC. The fluorescence was observed by a Zeiss A l 
inverted fluorescence microscope. The chromosomes were detected concomitantly by 
DAPI staining to prove the in situ  DNA damage.
4. Ex vivo 1C embryo p-Mek 1/2 In Situ IF Staining for Embryo C-Raf Activity
Activity o f the C -R af in the developing embryo plays a key role in the MAPK 
pathway for 1C to 2C transition and post- implantation embryo development. The 
inhibitory nature o f Vemurafenib on the C -Raf protein hinders development o f  the 
embryo. C -Raf by nature is a kinase (phosphotransferase) which phosphorylates its only
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substrate Mek by adding a phosphate group on it at Serine 217 and 221 in the mouse.
Mek 1/2 is the direct and only substrate o f  C-Raf in the MAPK pathway. The 
phosphorylation o f Mek 1/2 directly reflects the kinase function and activity o f C-Raf. the 
potential target o f Vemurafenib. Therefore, C -Raf activity in Vemurafenib-exposed 2C 
embryos was collectively tested by the embryo p-Mek 1/2 in situ IF Staining. 
Phosphorylated Mek 1/2 was subjected to indirect IF staining with signal amplification 
by biotin-streptavidin system. Results were examined under a Zeiss A l inverted 
fluorescent microscope.
5. Laboratory Quality Control and Quality Assurance
To ensure optimal quality and repeatability o f  experiment results, all equipment 
involved in each assay was closely monitored. In order to maintain in a constant pH o f 
the medium at the physiological pH 7.4, CO2 levels o f  5% in the water jacketed incubator 
(Model, NU4750) were checked on daily basis. A Fyrite CO2 indicator was used to 
guarantee exact CO2 levels in the event that the sensor o f the incubator became either 
disabled or disturbed by other factors (e.g. humidity). The optimal growth temperature 
for mouse embryos is 37°C. Incubator temperatures did not deviate from this optimal 
temperature by more than 0.5°C. A thermometer was inserted in the middle o f  the 
incubator chamber to guarantee temperature accuracy in the event that the sensor o f  the 
incubator was not working properly. Internal humidity was maintained by use o f a 
humidity pan at the bottom o f the incubator chamber which held a maximum o f 5L o f 
distilled water. To insure that temperature remained constant, water was not added 
during a culture cycle. The incubator was dismantled and cleaned once every three 
months or at any time that evidence o f bacterial growth was noted.
Deionized water was used for the surgical instrument sterilizer and was changed 
monthly. Surgical stainless steel instruments were placed in the sterilizer for a minimum 
o f three minutes prior to use under sterile conditions. Test-tube block heaters were 
disinfected weekly with STX-100 solution. The tolerance limit for block heaters was 
37°C ± 0.5°C and a thermometer was used for temperature guarantee.
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Temperatures o f the Revco deep freeze and refrigerator were checked daily. 
Tolerance limits for the freezer were -15°C ± 5°C for IF staining preservation. 
Temperature ranges between 5°C and 0°Cwere maintained in the refrigerator for 
formulated media and other hormones. All chemicals for formulation o f culture media 






(A, B and C)Pictures from one cell show A, M il stage; B, Misaligned shaped spindle; C, 
Unaligned aligned chromosome.
(D, E and F) Pictures from one cell show D, MI; E, Barrel spindle fiber; F. Unaligned 
chromosome.
Concentration related response o f spindle apparatus formation and chromosome 
alignment (GV, GVBD, and M il) after 16h in the presence o f Vemurafenib. Figures 
showed the immunofluorescence staining o f different responses o f  oocytes under the 
influence o f Vemurafenib. MI = Metaphase I; M il = Metaphase II. Cell was taken by 
DAC phase. Spindle fiber was stained as green and chromosomes were stained as blue.
(A, B, and C) Pictures from one cell show A, M il stage; B, TUNEL negative; C, aligned 
chromosome.
Concentration related response o f DNA integrity (GV, MI, and M il) after 16h in presence 
o f Vemurafenib. Figures showed the TUNEL IF staining o f different responses o f 
oocytes under influence o f  the Vemurafenib. MI: Metaphase I; MIL Metaphase II. Cell 
was taken by phase. Positive TUNEL was stained as green and chromosomes were 
stained as blue. Polar body showed a positive TUNEL (green, internal control).
(A, B and C) Pictures from one cell show A, abnormal 1C B, p-Mek 1/2 IF staining 
negative (Green stained cytoplasmic substances); C, DAPI stained nucleus location 
(D, E and F) Pictures from one cell show D, normal 2C; E, p-Mek 1/2 IF staining positive 
(Green stained cytoplasmic substances); F, DAPI stained nucleus location.
Concentration related response o f embryo C -Raf activity by after 16h in presence o f 
Vemurafenib. Figures showed the p-M ek 1/2 IF staining o f different responses o f 
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